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Abstract 
To evaluate the methodological quality of randomised trials in recently published 
articles and to examine the associations between methodological quality and bias, 
three related investigations were undertaken. First, to ensure the development of 
useful measures for the adequacy of randomisation, approaches to allocation were 
assessed as reported in 206 parallel group trials published in recent volumes of 
journals of obstetrics and gynaecology. Next, a study was conducted of associations 
between methodological quality and treatment effects. The material analyzed came 
from 250 trials in 33 meta-analyses on pregnancy and childbirth topics. Finally, the 
reported approaches to blinding and handling of exclusions were assessed from a 
random sample of 110 of the 206 previously identified reports. 
In the 206 published trials, 77% reported either inadequately or unclearly concealed 
treatment allocation. Additional analyses suggest that non-random manipulation of 
comparison groups may have occurred. 
In the next study. compared with trials in which authors reported adequately 
concealed treatment allocation, trials in which authors reported inadequately or 
unclearly concealed allocation yielded larger estimates of treatment effects (p<O.OO I). 
Odds ratios were distorted by 41% and 33%, respectively. Those associations likely 
represent bias and are particularly disconcerting in light of the results above from 
recently published trials. Lack of double-blinding in trials was also associated with 
larger treatment benefits. However, trials in which authors reported excluding 
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participants after randomisation were not associated with larger treatment effects. 
That lack of association appeared to be due to incomplete reporting. 
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The analysis of 110 recently published trials also supported the fmdings that some of 
the trials not reporting exclusions may actually have had exclusions. In practice, that 
incomplete reporting could lead to misinterpretations of trial quality. Moreover, only 
about half the trials that could have double-blinded actually did so. When 
investigators attempted double-blinding, only 16% provided any written assurances of 
successfully implementing blinding and only 6% tested its efficacy. 
PlaD n..., K.F. Sell ... 
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Chapter 1 
1. Introduction 
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1.1 Synopsis of background 
Comparisons of different forms of health interventions can be misleading unless 
investigators take precautions to ensure that, prior to receiving care, their study 
contains unbiased comparison groups with respect to prognosis. In controlled trials of 
prevention or treatment, randomisation produces unbiased comparison groups by 
avoiding selection biases. That characterizes randomisation's only unique strength. 
That strength, however, becomes of crucial importance in the potentially common 
circumstance where the treatment effects may be of comparable magnitude to the 
biases that plague most non-randomised comparisons of alternative forms of treatment 
and prevention. 
Even in view of the central importance of randomisation for achieving unbiased 
comparisons, authors often inadequately detail the steps taken to assign participants to 
comparison groups in trials. If randomisation indeed prevents bias as suggested, 
trials that have failed to report adequate approaches to ensuring proper randomisation 
should yield systematically different estimates of treatment effects compared with 
those derived from trials that have apparently used adequate approaches. Moreover, 
trials that have failed to report adequate approaches to other important methodological 
components of trials, such as blinding and the handling of exclusions, might well also 
yield systematically different estimates of treatment effects. 
Meagre evidence exists, however, in support of those presumptions. One study found 
that trials that did not take precautions to conceal treatment allocation schedules from 
those responsible for recruiting and entering participants yielded larger estimates of 
PbD nu: IU'. Sella" CIa.ptel' 1 17 
treatment effects than trials in which allocation had been adequately concealed 
(Chalmers et al. 1983). Another study sought an association between overall 
measures of methodological quality of each trial and estimates of treatment effects 
(Emerson et al. 1990). It did not detect such an association. Methodological aspects 
of their approach, however, may have handicapped their ability to accurately assess 
L 
the relationship. Other specific, independent effects, such as ~ding and handling of 
exclusions, do not appear to have been systematically evaluated. 
Other secondary analyses from meta-analyses have examined the relationship between 
study quality and estimates of treatment effects. Apart from a few exceptions, 
associations between methodological quality of studies and estimates of the size of 
difference between experimental groups within them usually occur because 
methodologically inferior studies tend to yield larger differences than those that have 
employed sounder methods for reducing bias (Chalmers et al. 1989). However, the 
preponderance of those investigations were subject to post-hoc reasoning and, thereby, 
largely serve a hypothesis-generating function. 
Non-randomised comparisons also tend to yield larger treatment effects than 
randomised comparisons in controlled trials. That supports the tendencies of the 
findings alluded to above. Thus, available evidence leans toward suggesting that trials 
that have failed to report adequate methodological approaches yield larger estimates of 
treatment effects than those derived from trials that have apparently used adequate 
approacho •. 
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1.2 Research aims 
As one important focus of the research in this thesis, the association was examined 
between methodological approaches intended to control bias in trials and estimates of 
treatment effects. That focus was envisaged to lead the research in the direction of at 
least two potential benefits: (1) if the results supported prior suggestive fmdings, 
documentation and dissemination of the importance of adherence to proper design 
principles in the conduct of RCTs would likely spur greater methodological rigour in 
the conduct and reporting of primary RCTs; and (2) for future meta-analyses, 
knowing the effect of methodological quality on treatment effects in primary studies 
would aid in the establishment of exclusion criteria and in the approach to the 
quantitative synthesis. 
In the examination of the associations between methodological approaches and 
treatment effects, a database was used of systematic reviews of controlled trials in 
pregnancy and childbirth (Enkin et al. 1993). Broad entry criteria for primary trials 
included in the reviews meant that the trials within this analysis varied in quality from 
well-done RCTs to poorly-done trials where a systematic method of assignment was 
utilized, such as alternate assignment or assignment by odd or even birth date. That 
heterogeneity presented an excellent scientific opportunity to study the relationship 
between methodological quality and effect sizes among trials that otherwise had 
sufficient similarity to be considered as part of one overview exercise (Sacks et aI. 
1987; Chalmers et aI. 1987a; Chalmers et al. 1987b). While all researchers prefer 
studies to be of uniformly high quality, in this analysis the net result of heterogeneity 
in study quality was a better chance to delineate factors associated with that variation. 
PbD Tbu: K.F. Sdlalz Cbapter 1 19 
Quality measures of four primary components were used in the analysis: allocation 
concealment, exclusions after randomisation, blinding, and generation of the 
randomisation sequence. Broad agreement appeared to exist that those were the most 
critical elements in trial design for safeguards against bias (Chalmers et al. 1990; 
Emerson et al. 1990; Colditz et al. 1989; Miller at al 1989; Gmzsche 1989; Peto 
1987; Collins et al. 1987; Pocock 1982). 
As a second important focus of this thesis, the methodological quality of RCTs was 
evaluated as reported in recently published articles. That work was important in and 
of itself, but it also served three other important functions relative to the analysis of 
the association between quality and treatment effects. First, it proved necessary to 
ensure that useful measures for the adequacy of randomisation had been developed. 
Second, it served as a valuable resource to put those results in context. And third, it 
provided more detailed data on the handling of exclusions after randomisation that 
clarified and supported some of those results from the association analysis. The 
following section contains descriptions of the temporal progression of the research and 
its location in this thesis. 
1.3 Description of ensuing chapters 
Chapter 2 provides background on randomisation, terminology, and previous research. 
Chapter 3 describes research performed before the analysis of association. The 
adequacy of the descriptions of randomisation and related topics from current journals 
of obstetrics and gynaecology were analyzed. That work aided in the development of 
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measures used for the adequacy of randomisation in Chapter 4 and provided a context 
for those results. 
Chapter 4 addresses the analysis of the association between methodological measures 
to control bias and estimates of treatment effects. The results from that work posed 
more questions on the adequacy of approaches to blinding and the handling of 
exclusions. In Chapter 5, the adequacy of information on those topics in current 
journals of obstetrics and gynaecology was addressed. 
Last, in Chapter 6, some overall comments are offered on the rmdings in this thesis 
and on further avenues of research. 
1.4 Focus on obstetrics and gynaecology 
This research focused on obstetrics and gynaecology for at least four reasons. First, 
and most importantly, the unique database that facilitated the analyses of 
methodological quality and bias, the Oxford Database of Perinatal Trials (Chalmers 
1992), predominantly contains trials in obstetrics. Second, the subject areas in 
obstetrics and gynaecology are relatively well-suited for RCTs, particularly in 
obstetrics where outcome events generally occur more quickly and, consequently, 
require shorter follow-up times. Third, while perhaps well suited for RCTs, others 
have reported that of all medical specialties, clinical practice in obstetrics and 
gynaecology was least likely to be supported by scientiftc evidence (Cochrane 1979; 
Office of Technology Assessment 1983). While that dubious distinction has been 
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retracted in England by Cochrane (Chalmers et al. 1989) largely through the activities 
of the National Perinatal Epidemiology Unit in Oxford, vast improvements in the 
quality of research remain necessary (Institute of Medicine 1992). Thus, 
methodological work in obstetrics and gynaecology might yield particularly rewarding 
scientific gains. And fourth, a comprehensive analysis had not occurred of the 
methodological quality of RCTs published in the literature from obstetrics and 
gynaecology. 
While this research may be particularly important to obstetrics and gynaecology, it 
may also have important implications for other medical specialties. In particular, the 
research addressing the association between the methodological quality of trials and 
treatment effects has implications for the design, implementation and analysis of all 
RCTs, as well as for the conduct of meta-analyses of RCTs. Even the research issues 
addressing the scientific quality of RCTs in the literature of obstetrics and 
gynaecology can give those in other medical specialties an indication of the scientific 
rigour they would expect to find in their journals. 
22 
Chapter 2 
2. Background 
CII'pm 1 
2.1 Advantages of randomisation 
A comparative clinical trial may be defmed as an experiment designed to assess the 
relative effectiveness of two or more treatments (exposures). Since investigators 
strive to identify the better treatment if one exists and to convince others of the 
validity of the results, they need to design and conduct trials carefully to minimize 
bias. 
23 
Until relatively recently in medical and public health history, investigators rarely used 
formally controlled experimentation. Over the twentieth century, the controlled 
clinical trial has gained increasing recognition as the best approach to evaluating 
health care and prevention alternatives, and the number of trials published has 
increased (Fletcher and Fletcher 1979). A relatively recent development has been the 
use of randomisation in the assignment of participants to comparison groups. 
R. A. Fisher developed randomisation as a basic principle of experimental design in 
the 1920s. The successful adaptation of randomised controlled trials (RCTs) to health 
care took place in the late 1940s, largely due to the advocacy and developmental work 
of Sir Austin Bradford Hill while at the London School of Hygiene and Tropical 
Medicine (Armitage 1982). His efforts resulted in the first use of random numbers to 
allocate trial participants (Medical Research Council 1948). Many of the critical 
design elements espoused in his early writings remain relevant to this day (Hill 1952). 
At least three major advantages of randomisation exist. First, it eliminates bias in the 
assignment of treatments. That is, treatment comparisons will not be prejudiced by 
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selection of patients of a particular kind, whether consciously or not, to receive a 
particular form of treatment. The concept of avoiding bias includes eliminating it 
from the acceptance or rejection of participants for the study as well as eliminating it 
from the assignment of participants, once accepted, to treatment. Proper registration 
of each participant immediately upon determination of eligibility for the trial, but 
before the randomised assignment is known, will prevent bias. 
Second, random allocation facilitates various devices for blinding the identity of 
treatments to the investigators, participants, and evaluators, including the possible use 
of a placebo (Armitage 1982). Those devices enable bias reduction in a trial after 
assignment. They would be difficult, perhaps even impossible, to implement if 
investigators assigned treatments in a non-random fashion. 
Third, random assignment permits the use of probability theory to express the 
likelihood that any difference in outcome between treatment groups merely reflects 
chance. While many view this advantage lightly, it has received greater recognition 
in the epidemiological community of late (Greenland 1990). 
2.2 Terminology 
The only unique strength of randomisation as an element in the design of treatment 
comparisons is that, if successfully accomplished, it eliminates selection bias at the 
point of trial entry. Successful abolition of selection bias at trial entry depends on 
successfully fulfilling two interrelated, prior conditions. First, an unpredictable 
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schedule, based on some chance (random) process, must be generated for assigning 
people to comparison groups in the trial. Second, steps must be taken to secure strict 
implementation of this schedule of random assignments. Generating a schedule of 
random assignments presents fewer problems than ensuring strict adherence to it. The 
key to achieving strict adherence to a schedule of random allocation is to prevent 
foreknowledge of treatment assignments among those involved in recruiting 
participants to the trial. 
Simple (unrestricted) randomisation can be achieved using one of the long-
established methods of 'drawing lots', such as repeated coin-tossing, throwing dice or 
dealing previously shuflled cards. More usually it is achieved by referring to a 
printed list of random numbers, or to a list of random assignments generated by a 
computer. Simple randomisation generates unbiased comparison groups, regardless of 
sample sizes. In trials with large sample sizes, the comparison groups would probably 
end up being of relatively similar sizes. In trials with small sample sizes, however, 
simple randomisation could result in comparison groups that would differ relatively 
more in sizes. 
Balanced (restricted) randomisation is used to ensure not only that comparison 
groups will be unbiased, but also that they will be of approximately the same size. 
The most frequently used method of achieving balanced randomisation is by 
'blocking'. Blocking ensures that the numbers of participants to be assigned to each 
of the comparison groups will be balanced within blocks of, say, every 10 
consecutively entered participants. The block size may remain fixed throughout the 
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trial or it may be randomly varied, to reduce the likelihood of foreknowledge of 
treatment assignment among those recruiting participants. 
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Other approaches to restricted randomisation include the 'biased coin' and 
'replacement randomisation' methods (Pocock 1983). Briefly, the 'biased coin' 
approach alters the allocation probabilities during the course of the trial to rectify 
imbalances that may be occurring. Replacement randomisation involves the repetition 
of a simple randomisation allocation scheme until a desired balance is achieved. 
To achieve benefits from pre-randomisation stratification, restricted randomisation is 
used to generate separate randomisation schedules for stratified subsets of participants 
defined by potentially important prognostic factors (for example, disease severity and 
study centres). Another good approach called 'minimisation' incorporates both the 
general concepts of stratification and restricted randomisation (Pocock 1983). It can 
be used to make small groups closely similar with respect to several characteristics. 
A less than optimal, but probably acceptable, restricted randomisation method is the 
'restricted shufiled' approach. It involves determining the desired sample size, 
apportioning the number of specially prepared cards for each treatment according to 
the allocation ratio, inserting the cards into opaque envelopes, sealing, and shufiling 
to produce a form of random assignment The envelopes should then be sequentially 
numbered. 
The restricted shuffied approach is less than optimal for at least three reasons. First, 
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shuffling cards determines the allocation sequence rather than a random number table 
or generator. Second, while correctly implemented envelopes can be adequate, they 
are more open to deciphering than other approaches. And third, balance would only 
usually occur at the end of the trial and not throughout. 
Systematic methods of assignment may at first glance appear to be reasonable, but 
fail under closer scrutiny for both theoretical and practical reasons. These methods, 
such as assignment based on date of birth, case record number, date of presentation, 
or an odd or even number in the order of presentation in a consecutive series of 
participants, are just not random. Sometimes they are referred to as 'quasi-random', 
but even this may give a falsely optimistic impression. For example, in some 
populations, the day of the week on which birth occurs is not a matter of chance 
(Macfarlane 1978). While an element of chance is certainly involved in some of 
these approaches, to confmn that the assignments were at least close to being random 
might entail undertaking a separate, more time-consuming study than the primary 
substantive study planned. If authors report using systematic allocation, readers 
should be wary of the results. Investigators conducting trials should not expose their 
work to such scepticism by using systematic methods. Using an appropriate, random 
approach is easier in the short- and long-run, and reproducible. 
An even more important weakness with systematic methods centres on the near 
impossibility of concealing the assignment schedule. That allows foreknowledge of 
treatment assignment among those recruiting participants to the trial. Por that reason 
the British Medical Journal has recently decided not to publish trials that have used 
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such allocation schemes when randomisation was feasible (Altman 1991). 
2.3 Randomisation without foreknowledge 
Randomisation encompasses both the approach to generating the random sequence and 
the approach to concealing those assignments until the point of actual treatment 
allocation. While generating a random sequence is important, concealment of 
assignments from everyone involved in the trial may contribute more to producing 
randomisation without foreknowledge (peto 1987). 
Reducing bias in trials crucially depends upon preventing that foreknowledge. When 
assessing a potential participant's eligibility for a trial, those responsible for recruiting 
participants should remain unaware of the next assignment in the sequence until after 
the decision about eligibility has been made. Then, after the assignment has been 
revealed, they should not be able to alter the assignment or the decision about 
eligibility. The ideal is for the process to be impervious to any influence by the 
individual allocating treatment. 
The process of concealing assignments until treatment has been allocated has 
sometimes confusingly been referred to as 'randomisation blinding' (Chalmers 1983). 
The main reason for that term being unsatisfactory is that, on the rare occasions that it 
has been used at all, it has too seldom been distinguished clearly from other forms of 
blinding (masking) - of patients, physicians, outcome evaluators, and analysts. That is 
unsatisfactory for at least three reasons. First, the rationale for generating comparison 
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groups at random, including the steps taken to conceal the assignment schedule, is to 
eliminate selection bias. By contrast, other fonns of blinding, used after the 
assignment of treatments, serve primarily to reduce ascertainment bias. Second, from 
a practical standpoint, concealing treatment assignment up to the point of allocation is 
always possible, regardless of the study topic, whereas blinding (masking) after 
allocation is not attainable in many instances, such as in trials comparing surgical with 
medical treatments. Third, control of selection bias is relevant to the trial as a whole, 
and thus to whatever outcomes are being compared, whereas control of ascertainment 
bias is often 'outcome-specific', that is, it may be accomplished successfully for some 
outcomes in a trial, but not for others. Thus, 'blinding' up to the true allocation of 
treatment and blinding after it are addressing different sources of bias, are inherently 
different in their practicability, and may apply to different parts of a trial. In light of 
these reasons for distinguishing the different forms of blinding clearly, the process of 
concealing assignments will be referred to as 'allocation concealment' or 
'randomisation concealment', and the term 'blinding' (masking) will be reserved for 
measures taken to reduce bias after treatment has been assigned. 
Investigators likely achieve allocation concealment if a randomly generated 
assignment schedule is administered by someone who is not responsible for recruiting 
participants, for example, someone based in a trial office, or pharmacy. If organising 
allocation in that way is not possible, then other precautions are required to try to 
prevent manipulation of the schedule of random assignment by those recruiting 
partfcfpantl to the trial. Tho .. Include. for example, Ullna numbered or coded bonl ... 
ampoules or other containers, or using serially numbered, sealed, opaque envelopes 
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(Altman and Dore 1990; Pocock 1983; Mosteller 1980). Simply using an open list 
('table' or 'schedule') of random assignments is as open to manipulation as is 
dependence on one of the systematic methods of assignment. 
2.4 Review of previous relevant research 
2.4.1 Non-randomised comparisons and bias 
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The elimination or reduction of bias and the production of comparable treatment 
groups exemplify good ReT methodology. If that is indeed true, bias should be 
detectable in non-randomised as compared to randomised studies. That has been 
illustrated in a number of instances. One example of bias in historical comparisons is 
provided by studies of anticoagulant therapy in the hospital phase of an acute 
myocardial infarction for which 18 trials with historical controls and 6 with 
randomised controls were reviewed (Chalmers et ale 1977; Pocock 1979). The 
historically controlled trials with over 8,000 patients resulted in a 53% reduction in 
mortality for anticoagulant therapy compared with no treatment, whereas the RCTs 
involving almost 4,000 patients showed only a 20% mortality reduction. "Although 
both types of study confl11ll that anticoagulant therapy improves survival, it is 
disturbing that the average bias incurred by using historical controls is of the same 
order of magnitude as the observed treatment effect" (Pocock 1979). 
In another example, the literature was searched to identify therapies studied by both 
RCTs and historically controlled trials (HCTs). Six therapies were found for which 
50 RCTs and 56 HCTs were reported (Sacks et a1. 1982). Forty-four of 56 HCTs 
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(79%), found the therapy better than the control regimen, but only 10 of 50 RCTs 
(20%) agreed. The same trend emerged when the authors examined each of the six 
therapies separately. They concluded that the data suggest that biases in patient 
selection may irretrievably weight the outcome of HCTs in favour of new therapies. 
While Sacks et al. appeared to examine similar outcome measures between RCTs and 
HCTs, they did not clarify the degree of similarity. Any potential dissimilarity would 
be unlikely, however, to account for the large discrepancies observed. 
Another study examined controlled clinical trials of the treatment of acute myocardial 
infarction (Chalmers et al. 1983). Fifty-seven randomised studies were compared with 
43 non-randomised studies, which included the use of both simultaneous and historical 
controls. Differences in case-fatality rates between the treatment and control groups 
at p<0.05 were found in 8.8% of the randomised studies and 58% of the non-
randomised studies. In these statistically significant studies, results favoured the 
treatment group over the controls in 60% and 93% of the studies, respectively. While 
the large difference in the proportion of statistically significant studies could partially 
be a function of larger sample sizes in the non-randomised studies as well as a 
function of bias, bias was clearly evident when the mean differences (± standard 
error) in case fatality rates were examined: 0.003 ± 0.008 (not significant) for the 
randomised group and 0.105 ± 0.017 (p<0.001) for the non-randomised group. 
Similarly, other examinations of medical and surgical disciplines have observed that 
non-randomised studies tend to report larger gains than do the randomised studies 
(Mlller It at. 1989: Coldltz et at. 1989). ThUi. that randomilOd VerIUI non-
randomised comparisons reduce bias appears well documented and generally accepted 
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by the scientific community. 
2.4.2 Methodological rigour and bias in randomised comparisons 
Less supportive information exists on methodologically sound randomisation schemes 
reducing or eliminating bias compared to less rigorous or haphazard schemes. One 
notable exception is the study that examined the controlled clinical trials of the 
treatment of acute myocardial infarction (Chalmers et al. 1983). The authors 
compared 57 papers in which the randomisation process was concealed (more 
methodologically rigorous) with 45 papers in which it was not concealed (less 
methodologically rigorous). Differences in case-fatality rate between treatment and 
control groups at p<O.OS were found in 8.8% and 24.4% of the trials, respectively. 
That large discrepancy could have been partly the result of larger sample sizes as well 
as bias in the less methodologically rigorous randomised trials. The sample sizes 
were not provided in that report, however, but they likely approximated those of the 
more methodologically rigorous trials since all were controlled trials. If anything, less 
rigorous trials usually tend to have smaller sample sizes. 
Bias seems the more likely explanation. The authors examined the mean differences 
(± standard error) in case-fatality rates: 0.003 ± 0.008 (not significant) for the 
concealed randomisation group and 0.052 ± 0.016 (p<O.OOI) for the unconcealed 
randomisation group. The disparity between the mean differences is a clear indication 
of potential bias in the unconcealed randomisation group. Moreover, in the 
statistically significant studies, results favour the treatment group over the controls In 
60% and 100%, respectively. The authors conclude that the "data strongly suggest 
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that bias in treatment assignment could be a more important determinant of outcome 
than the treatments under investigation." 
While these results appear convincing, one caveat should be considered. Whereas the 
outcome, death, is the same for all studies included in the analysis, a number of 
different treatments were aggregated for the analysis and the distributions of these 
treatments for the concealed randomisation category and the unconcealed 
randomisation category were different. Thus, different treatments as well as bias 
could be contributing to the differences between the two randomisation groups 
(Gillman and Runyan 1984). 
Another study addressed this flaw by comparing similar treatments and similar 
outcome measures (Emerson et al. 1990). The authors examined seven meta-analyses 
using general linear models, which combined features of analysis of variance and 
regression, and introduced a categorical variable that distinguished the seven topics 
from one another. Thus, they essentially controlled for each meta-analysis and 
compared similar treatments with similar outcome measures. The authors found that 
an overall measure of RCT quality, used as previously reported (Chalmers at al. 
1981), did not have a statistically significant relationship to the primary study's 
treatment differences within the meta-analyses. 
That apparent lack of a relationship in the Emerson et al. study may have at least two 
potential explanations. First, and most important, the authors used a measure of 
quality (Chalmers et al. 1981) that quantifies many facets of trial design and analysis, 
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some of which were not likely to be related to bias. Second, they included a measure 
of study size as an independent variable along with the measure of quality in their 
linear model. However, study size correlated with quality score so it, through 
difficulties with multicollinearity, could have obscured the effect of other aspects of 
quality. 
The authors also examined the relationship between the variability of the treatment 
difference and overall quality score, i.e. attempting to determine whether lower quality 
studies tend to produce more variable estimates of treatment differences. That lower 
methodological quality would produce bias in both directions and thereby cause 
increased variability appears plausible and a worthwhile hypothesis to test. They 
concluded that no evidence was found for greater variability but, again, the 
methodology they used may have been insufficiently sensitive. Their paper did not 
clearly specify whether they had controlled for the individual meta-analyses in this 
instance. 
Chalmers et al. (1983) and Emerson et al. (1990) conducted perhaps the most 
comprehensive scientific investigations to date of methodological quality and bias in 
RCTs. The earlier study was persuasive of a relationship whereas the more recent 
was inconclusive, perhaps partly due to its design. 
Secondary analyses from meta-analyses have examined the relationship between study 
quality and the estimate of the magnitude of the dltTerence between .tudy aroUPI 
compared. In some, no relationship was found, but in a greater number a relationship 
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was found (Chalmers et al. 1989). One recent meta-analysis of low-molecular-weight 
heparin versus standard heparin in general and orthopaedic surgery observed the 
relationship in general surgery but not in orthopaedic (Nurmohamed et al. 1992). 
Apart from a few exceptions, associations between methodological quality of studies 
and estimates of the size of difference between experimental groups within them 
usually occur because methodologically inferior studies tend to yield larger differences 
than those that have employed sounder methods for reducing bias (Chalmers et al. 
1989). However, the preponderance of these investigations were not analyzed 
statistically and were subject to post-hoc reasoning and, thereby, largely serve a 
hypothesis-generating function. 
The Chalmers et al. (1983) study specifically examined the association between the 
concealment of the allocation schedule and estimates of treatment effects. 
Unfortunately, other important, specific, methodological compo~ents of trials, such as 
blinding or the handling of exclusions, appear not to have been similarly examined. 
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Chapter 3 
3. Assessing the Quality of Randomisation and 
Allocation from Reports of Controlled Trials 
Published in Obstetrics and Gynaecology Journals 
36 
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3.1 Summary 
3.1.1 Objective. To assess the quality of randomisation, allocation, and other 
associated methodological components from reports of trials in obstetrics and 
gynaecology jownals. 
3.1.2 Methods. Evaluation of all 206 reports of parallel group trials. in which 
authors stated allocation to have been randomised. published in the 1990 and 1991 
volumes of four jownals of obstetrics and gynaecology. 
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3.1.3 Results. Only 32% reported having used an adequate method to generate 
random numbers, and only 23% contained information showing that steps had been 
taken to conceal assignment until the point of treatment allocation. A mere 9% of the 
reports of trials published in the obstetrics and gynaecology jownals described 
adequate methods of randomisation. In reports of trials which had apparently used 
unrestricted randomisation, the differences in sample sizes between treatment and 
control groups were much smaller than would be expected by chance. In reports of 
trials in which hypothesis tests had been used to compare baseline characteristics, only 
2% of reported tests were statistically significant, lower than the expected rate of 5%. 
3.1.4 Conclusions. The generation of unbiased comparison groups in controlled 
trials requires proper randomisation. Yet, authors usually provided inadequate 
information or described an inadequate approach. Additional analyses suggested that 
non-random manipulation of comparison groups and selective reporting of baseline 
comparisons may have taken place. 
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3.2 Introduction 
Randomisation avoids selection biases in controlled trials of prevention and treatment. 
Over forty years ago, Austin Bradford Hill (1952) wrote that " ... having used a random 
allocation, the sternest critic is unable to say when we eventually dash into print that 
quite probably the groups were differentially biased through our predilections or 
through our stupidity". 
Methodologically rigorous approaches to randomisation, however, must be used. If 
investigators improperly implement or inadequately describe the methodology, the 
results, and thereby conclusions, emanating from those trials should be considered as 
potentially biased (Mosteller et al. 1980; Altman and Dore 1990). Furthermore, while 
randomisation allocates treatment without bias, it does not necessarily produce similar 
groups on important prognostic factors. Chance imbalances can occur. The similarity 
of baseline characteristics should be established, with hypothesis tests not being the 
criterion (Altman 1985). Not only should participants be allocated to treatment 
groups properly, but the sample sizes should be properly planned as well (Freiman et 
aI. 1978). 
Unfortunately, investigators often improperly address the process of randomisation in 
the design and implementation phases of controlled trials, and authors often neglect it 
in published reports. For example, in 132 reports of trials on cancer topics, only a 
third of the authors reported how the randomisation had been carried out (Mosteller et 
aI. 1980). Moreover, many of the methods specified were, in fact, non-random, such 
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as using date of birth, using admission number or identification number, or using an 
odd-even method of assignment. 
Even in some of the most highly regarded medical journals, the quality of reporting 
leaves considerable room for improvement. Less than a fifth of the reports of clinical 
trials published during 1979-80 in the New England Journal of Medicine (NEJM), 
the Lancet, the Journal of the American Medical Association, and the British 
Medical Journal (BMJ) described the method of randomisation (DerSimonian et al. 
1982). 
An analysis by Altman and Dore (1990) of reports of trials published during 1987-8 
in the BMJ, the Lancet, the NEJM, and the Annals of Internal Medicine revealed 
that only 34% of the articles specified both the method used to generate random 
numbers and the mechanism used to allocate treatments; and even when methods were 
specified, they were often not methodologically sound (Altman and Dore 1990). 
While perhaps an improvement compared with the results from the early 1980s, 
obviously much capacity remains for further improvement. 
The analysis also revealed that 49% of trials had reported baseline data 
unsatisfactorily, and that 58% had inappropriately used hypothesis tests to compare 
baseline variables (Altman and Dore 1990). Overall, 600 tests were reported, of 
which only 4% were statistically significant at the 5% level. Furthermore, their 
analysiS also illustrated that among trials that used Simple randomisation, the sample 
sizes in the two comparison groups were too often similar (Altman and Dore 1990). 
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Altman and Don~'s survey of widely read and highly regarded general medical 
journals prompted a suggestion that the standard of reporting in specialist medical 
journals was likely to be even worse (Pignon and Poynard 1990). Apparently, no 
systematic analysis of randomisation and allocation of journals from obstetrics and 
gynaecology has been undertaken, although assessments of reports of trials in that 
field have indicated that the methodological quality may indeed be worse than that of 
reports published in general medical journals (Tyson et al. 1982; Thacker 1987; 
Keirse 1988; Grimes and Schulz 1992). I undertook a study, resembling Altman and 
Dore's, of reports of randomised controlled trials (ReTs) in obstetrics and 
gynaecology. 
The systematic evaluation undertaken was conducted of reports published in the two 
main American and the two main British journals of obstetrics and gynaecology. The 
American Journal of Obstetrics and Gynecology (AJOG) and Obstetrics and 
Gynecology (OG) emanate from the United States and the ~ritish Journal of 
Obstetrics and Gynaecology (BJOG) and the Journal of Obstetrics and 
Gynaecology (JOG) from the United Kingdom. 
The reported approaches to treatment assigrunent and to comparison of baseline 
characteristics were analyzed. As indicated above, reports in the obstetrics and 
gynaecology journals were suspected to be of lower quality than reports published in 
the general medical journals. Furthermore, three primary hypotheses were proposed. 
Firat, the IUlplclon that the rcpOrtl publllhe6 In the BJOG woul6 be ot better quality 
than those published in other journals of obstetrics and gynaecology. A concerted 
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editorial effort had been made to improve the quality of reporting in that journal, 
including publication of a series of articles providing reporting standards for different 
types of studies (Bracken 1989; Wald and Cuckle 1989), including trials (Grant 1989). 
Second, the notion that, as had been demonstrated using reports of trials published in 
the general medical journals (Altman and Dore 1990), the numbers of patients in the 
comparison groups of trials that had apparently used unrestricted randomisation would 
be more similar than expected by chance. And third, the impression that, as had been 
suggested by the earlier study (Altman and Dare 1990), the percentage of reported 
statistically significant differences in characteristics measured at baseline would be 
less than the expected 5%. 
3.3 Methods 
3.3.1 Study material 
Data were collected from 206 reports of trials published in the 1990 and 1991 
volumes of the AJOG, the BJOG, the JOG, and OG, using a hand search to try to 
ensure that all the eligible reports were identified. In addition, both the Oxford 
Database of Perinatal Trials (Chalmers 1992; Chalmers et aI. 1986) and MEDLINE 
were searched as a cross-check. The study was restricted to reports of parallel group 
(uncrossed) trials, comparing two or more treatments, in which allocation was stated 
to have been randomised. Initial selection was based on the abstract and a cursory 
inspection of the main text. A report was included as long as it purported to refer to 
a randomlsed trial, even It the actual method at allocation described was non-random. 
Where possible, the actual method of allocation was recorded. Reports that were not 
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the first publications relating to particular trials were excluded. 
The reports were examined and the data collected using methods similar to those used 
in Altman and Dore's (1990) analysis of general medical journals. The data 
collection instrument was tested in a pilot study (articles from 1989 in the same 
journals) before proceeding with the assessments. For consistency of measurement 
across journals, I did all of the assessments. To examine the reproducibility of items 
on the questionnaire, David A. Grimes, M.D., Professor of Obstetrics and Gynecology 
at the University of California, San Francisco, assessed a random sample (random 
number table) of 15 trials blinded to the results of the initial assessments. We found 
no notable differences on the main outcome measures. The data were entered 
interactively into an EPI-INFO questionnaire with on-line editing, skip-pattern, and 
logic-checking capability (Dean et al. 1990). 
3.3.2 Aspects of the analytical approach 
The analysis of the differences in numbers of participants reported to have been 
assigned to comparison groups has been limited to two-group trials which were 
apparently 'unrestricted'. Trials were categorized as 'unrestricted' if they met all the 
following criteria: 1) the trial had not been reported to have been restricted; 2) the 
type of randomisation for the trial had either not been stated, or had been stated to 
have been 'simple' or 'unrestricted'; and 3) the trial had not been reported to have 
been 'stratified' (since stratified trials are more likely to be blocked). 
Comparison of baseline characteristics of the treatment groups is an important fust 
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step in trial reporting. Although randomisation assigns treatments without selection 
bias, it does not necessarily produce similar groups on important prognostic factors. 
Chance imbalances can and do occur. The probabilistic argument is that, on 
average, randomised groups will have the same characteristics. In practice, however, 
a particular trial may have one or more characteristics unequally split between groups. 
Large studies generate serious imbalances less frequently, but smaller studies using 
simple randomisation remain susceptible to substantial covariate imbalances (Lavori et 
al. 1983). 
Such imbalances in baseline characteristics cause concern, however, only when they 
involve characteristics related to outcome variables of prognostic importance. Then 
they can be confounding variables, albeit by chance, but confounding nonetheless. 
Testing for statistically significant differences (hypothesis testing) is not a valid basis 
on which to assess comparability in respect to baseline characteristics. Comparability 
must be assessed in terms of the prognostic strength of the variables and the 
magnitude of any imbalance (Rothman 1977; Lavori et al. 1983; Altman 1985). If 
means or medians for continuous variables are reported, appropriate information about 
variability should also be reported, e.g. the standard deviation, range, or raw data. 
In evaluating presentations of variability in this chapter, if some baseline 
characteristics within a particular report had variability presented and others had not, 
the assessment was based on the method used when variability had been presented. In 
assessing the results of hypothesis tests of baseline characteristics, the level of 
significance was assumed to have been 0.05 if it had not been stated explicitly. Only 
.110 n .. : K.F. Sc ..... CII.pier 3 44 
data were used for which the authors had presented test results. 
For the reasons offered in section 2.3, the process of concealing assignments is 
referred to as 'allocation concealment' or 'randomisation concealment', and the 
term 'blinding' (masking) is reserved for measures taken to reduce bias after treatment 
has been assigned. 
3.3.3 Statistical methods 
Unless otherwise indicated, chi-squared tests were used for comparing nominally 
scaled variables. The Greenland and Robins approach in EPI-INFO was used to 
obtain confidence intervals for relative risks (Dean et al. 1990). Because Bartlett's 
test for homogeneity of variance was typically statistically significant at p<O.OS, 
Kruskal-Wallis one-way analysis of variance tests were used to compare continuous 
variables among journals. Moreover, Kruskal-Wallis is a non-parametric test which 
does not assume normal distributions, yet it retains most of the power of a parametric 
test. 
To facilitate direct comparison of the reports published in these obstetrics and 
gynaecology journals with those published in general journals, frequent reference is 
made to Altman and Dore's (1990) article on the general medical journals in the 
discussion section. Henceforth, the results from that article are referred to as being 
from the 'general journals' without constant duplicate referencing. 
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3.4 Results 
3.4.1 Source of reports 
Of the 206 reports of trials published in the obstetrics and gynaecology journals, 64 
were found in the AJOG, 48 in the BJOG, 20 in the JOG, and 74 in OG. Other 
trials in these journals used systematic methods, but they were not included because 
they did not purport to be randomised. 
3.4.2 Type of randomisation 
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Over three-quarters (78%) of the reports of trials failed to provide information about 
the way that the treatment assignments bad been generated (Table 3.1). Moreover, 11 
reports (5%), about a quarter of those providing any information at all, clearly stated 
that a systematic method of assignment bad been used, despite their claims to be 
reporting randomised trials. 
Only 29 (14%) of the reports described the use of restriction, and of the 23 reports 
describing the use of blocking, only 15 (65%) stated the size of blocks. In the 
remaining reports of trials that had used restriction, four had used a restricted sbuftled 
approach, one the biased coin method, and one minimisation. No reports stated the 
use of replacement randomisation. 
Reports published in the BJOG stated the type of randomisation more frequently than 
reports published in the other journals (p<0.001, 3 df). The differences among the 
other three journals in this respect were not statistically significant (p=O.36, 2 dt). 
Reports published in the BJOG also more frequently reported using a restricted 
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approach to randomisation (p<O.OOI, 3 di). Only four trial reports stated that simple 
unrestricted randomisation had been used. 
Table 3.1 
The type of randomisation stated in the four 
obstetrics and gynaecology journals, 1990 and 1991 
Type of randomisation AmJ Br J Obstet J Obstet Obstet Total 
stated Obstet Gynaecol Gynaecol Gynecol 
Gynecol 
Simple (unrestricted) 0% 6% 5% 0% 2% 
(0) (3) (1) (0) (4) 
Balanced 6% 35% 5% 9% 14% 
(restricted) (4) (17) (1) (7) (29) 
Systematic 3% 6% 5% 7% 5% 
(2) (3) (1) (5) (11) 
Other 0% 0% 5% 0% 0% 
(0) (0) (1) (0) (1) 
Not stated 91% 52% 80% 84% 71% 
(58) (25) (16) (62) (161) 
Total 100% 100% 100% 100% 100% 
(64) (48) (20) (74) (206) 
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3.4.3 Stratification 
Only nine per cent of the reports of trials in the obstetrics and gynaecology journals 
reported the use of stratification (Table 3.2), and fewer than half of those reported the 
use of blocking or minimisation. 
Table 3.2 
Stratified trials and those stratified trials that report being blocked 
in the four obstetrics and gynaecology journals 
Stratification status AmJ Br J Obstet J Obstet Obstet Total 
Obstet Gynaecol Gynaecol Gynecol 
Gynecol 
Stratified· 5% 19% 0% 8% 
(3) (9) (0) (6) 
Stratified & 2% 10% 0% 3% 
blocked· (1) (5) (0) (2) 
• Includes the trial that used minimisation 
3.4.4 Methods for generating random numbers 
Only 32% of reports specified an adequate method for generating random numbers, 
with the rates being similar for the four journals (p=O.27, 3 df)(Table 3.3). A 
computer random number generator was the most frequently specified method (18%), 
followed by a random nwnber table (11 %). Other random processes used in 4% of 
9% 
(18) 
4% 
(8) 
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the trials primarily included shuffled cards and tossed coins. 
Table 3.3 
Methods for generating allocation sequences 
Method for Am] Br] Obstet ] Obstet Obstet Total 
generating sequence Obstet 
Gynecol 
Gynaecol Gynaecol Gynecol 
Computer· 20% 21% 5% 16% 18% 
(13) (10) (1) (12) (36) 
Random number 13% 8% 10% 11% 11% 
table· (8) (4) (2) (8) (22) 
Other possible 3% 8% 0% 3% 4% 
random process· (2) (4) (0) (2) (8) 
Systematic 3% 6% 5% 7% 5% 
(2) (3) (1) (5) (11) 
Not stated 61% 56% 80% 64% 63% 
(39) (27) (16) (47) (129) 
Total 100% 100% 100% 100% 100% 
(64) (48) (20) (74) (206) 
Any adequate 36% 38% 15% 30% 32% 
random process (23) (18) (3) (22) (66) 
• Adequate random process 
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3.4.5 Treatment allocation methods 
Almost half (48%) of the reports of trials did not describe the mechanism used to 
allocate treatments (Table 3.4). A quarter of the reports described the use of 
envelopes, but only a quarter of those reports stated that the envelopes had been 
sequentially numbered, opaque, and sealed. Fifteen trials specified that the allocation 
had been prepared by the pharmacy, another 15 that numbered bottles or containers 
had been used, and 5 that a form of central randomisation had been organised. Five 
percent of the reports stated that a list, table, or schedule had been used for allocation; 
in a further five percent, some form of systematic assignment procedure had been 
used. 
Overall, only 23% of the reports published in the obstetrics and gynaecology journals 
(Table 3.4) reported an adequate approach to randomisation concealment. The 
proportion of trials in which adequate randomisation concealment appeared to have 
been achieved varied markedly (p<O.OOl, 3 df) among the four journals (Table 3.4). 
The BJOG had a rate that was 2.6 times higher than the other three combined (95% 
CI 1.6-4.1, p<O.OOI). 
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Table 3.4 
Allocation concealment methods 
Allocation method AmJ Br J Obstet J Obstet Obstet Total 
Obstet Gynaecol Gynaecol Gynecol 
Gynecol 
Nwnbered or coded 8% 10% 0% 7% 7% 
containers· (5) (5) (0) (5) (15) 
Pharmacy concealed· 6% 10% 0% 8% 7% 
(4) (5) (0) (6) (15) 
Centrally concealed· 2% 6% 0% 1% 2% 
e.g. telephone (1) (3) (0) (1) (5) 
Sequentially 3% 17% 5% 3% 6% 
nwnbered, opaque, (2) (8) (1) (2) (13) 
sealed envelopes· 
Envelopes -- 20% 25% 10% 16% 19% 
other (13) (12) (2) (12) (39) 
List, table, 9% 4% 0% 3% 5% 
or schedule (6) (2) (0) (2) (10) 
Systematic 3% 6% 5% 7% 5% 
(2) (3) (1) (5) (11) 
Not stated or 48% 21% 80% 55% 48% 
described (31) (10) (16) (41) (98) 
Total 100% 100% 100% 100% 100% 
(64) (48) (20) (74) (206) 
Use of an adequate 19% 44% 5% 19% 23% 
allocation concealment (12) (21) (1) (14) (48) 
method 
• Adequate allocation concealment method 
.IaD n •• : JUl. ScIa ... Claap&er) 51 
3.4.6 Overall quality of randomisation and allocation 
Fifty-one reports of trials (25%) included information both on the method used to 
generate random numbers and on the mechanism used to allocate treatment, but only 
19 (9%) described both an adequate method of generating random numbers and an 
adequate method of randomisation concealment. The proportions for each were 15% 
for the BJOG, 9% for the AJOG, 7% for OG, and 5% for the JOG, but the 
differences among these proportions were not statistically significant (p=O.46, 3 df). 
3.4.7 Relative size of treatment groups in apparently unrestricted trials 
In 96 reports of apparently unrestricted trials, the differences in sample sizes between 
the treatment and control groups were much smaller than would be expected by 
chance alone. In Figure 3.1, about five trials should fall outside the outer pair of 
straight lines - none did; about 48 should fall outside the inner pair of lines - only 8 
did. The differences in group sizes were much smaller than would be expected by the 
play of chance (p<O.OOI, Chi-squared goodness-of-fit, 2 df). A further indicator of 
the similarity of group sizes is that 54% of the unblocked trials had differences in 
group sizes of zero or one. Surprisingly, the blocked trials yielded differences that 
were less similar overall, with only 36% of the trials having differences in group sizes 
of zero or one. 
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The relationship between the difference in sample sizes in the 
treatment and control groups and total study size for 96 unblocked 
trials. The straight lines represent the expected distribution due to the 
play of chance. Total study size is shown on a square root scale to 
make the confidence interval lines straight. The 95% confidence 
interval is approximately: 
±2 VTotal Study Size (Altman and Dore 1990). 
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3.4.8 Comparisons of baseline characteristics 
Comparisons of baseline characteristics were presented in 84% of the reports (Table 
3.5). They were most often presented in the BJOG. least often in the JOG. with 
reports in the AJOG and OG having intermediate and similar rates. However. the 
differences were not statistically significant (p=O.17; 3 df). 
53 
The median numbers of comparisons of baseline characteristics in those reports in 
which comparisons were presented was 6 (Table 3.5). Reports in the AJOG and OG 
tended to present a larger number of comparisons (p=O.008. 3 di). 
Comparisons of baseline characteristics presented as continuous variables were 
reported in 78% of the trials (Table 3.5). In those, 68% were accompanied by 
appropriate measures of variability. Reports in the BJOG were more likely than 
those in the other obstetrics and gynaecology journals to present appropriate measures 
of variability. but the differences among the four journals were not statistically 
significant (p=O.22; 3 di). In 41 % of the reports. overall. either authors did not 
present baseline characteristics, or did not report appropriate measures of variability. 
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Table 3.5 
Baseline characteristics 
AmJ Br J 
Baseline Obstet Obstet J Obstet Obstet 
characteristics Gynecol Gynaecol Gynaecol Gynecol Total 
All variables 
reported: 
~1 Presented for 81% 94% 75% 82% 84% 
each treatment Group (52) (45) (15) (61) (173) 
Median number 7 5 4 7 6 
presented (1-34) (1-32) (2-7) (1-58) (1-58) 
(range) 
Continuous variables 
only: 
~1 Continuous 80% 85% 70% 74% 78% 
variable reported (51) (41) (14) (55) (161) 
each group 
Median number 4 4 3 4 4 
presented (1-12) (1-18) (1-7) (1-14) (1-18) 
(range) 
Appropriate 65% 81% 57% 64% 68% 
variability· (33) (33) (8) (35) (109) 
Inappropriate 24% 17% 36% 24% 23% 
variabilityt (12) (7) (5) (13) (37) 
No measure of 12% 2% 7% 13% 90~ 
variability (6) (1) (1) (7) (15) 
reported 
• Standard deviation, range, centiles, or raw data 
t Standard error or confidence interval 
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3.4.9 Use of hypothesis tests to compare baseline characteristics 
Hypothesis tests were used to compare baseline characteristics in 61 % of the reports 
(Table 3.6). Hypothesis tests were presented far more often in the American journals 
than in the British (p<0.001, 3 df). Overall, 1,076 hypothesis tests were presented in 
125 reports. Only 2% of those were statistically significant at the 5% level; that 
itself is a statistically significant departure from expectation (p<O.OO 1, z-test). 
Table 3.6 
Use of hypothesis tests (tests of statistical significance) 
to compare baseline characteristics 
Comparing baseline AmI Br I Obstet IObstet Obstet Total 
variables Obstet Gynaecol Gynaecol Gynecol 
Gynecol 
Trials using 72% 35% 20% 78% 61% 
hypothesis tests (46) (17) (4) (58) (125) 
In those trials using 
hypothesis tests: 
Specified 87% 82% 75% 85% 85% 
test methods (40) (14) (3) (49) (106) 
Mean number 10.3 6.2 4.0 8.3 8.6 
tested (SD) (7.4) (5.1) (2.2) (5.8) (6.4) 
Total number 472 106 16 482 1076 
tested 
Percent (number) 2% 2% 0% 2% 2% 
statistically significant at (11) (2) (0) (9) (22) 
p<0.05 
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3.4.10 Power calculations 
In 50 (24%) of the reports, the sample sizes were reported to be based on prior 
statistical power calculations. The rates were 0% for the JOG, 18% for OG, 19% for 
the AJOG, and 52% for the BJOG. Trials published in the BJOG reported power 
calculations over three times more frequently than those from the other three journals 
combined (RR = 3.3, 95% CI 2.1-5.2, p<O.OOI). 
3.5 Discussion 
3.5.1 Importance of randomisation 
Randomisation is the only reliable way to create comparable comparison groups with 
respect to unmeasured or imperfectly measured prognostic factors. For that reason, 
RCTs have been widely accepted as providing the most valid basis for comparing 
interventions in health care. Indeed, of the various measures to control bias within a 
trial, proper randomisation is arguably the only one that can be confidently assumed 
to apply to the trial as a whole. All of the other steps which may be taken in an 
attempt to control biases ('blinding', and analysis by 'intention-to-treat', for example) 
may have been achieved successfully for some of the outcomes assessed in a trial, but 
not for others. Furthennore, and perhaps even more importantly, the virtual total 
success of randomisation can be guaranteed for all trials. By contrast, other measures 
used to control bias can not be implemented for some trials and, if they can be, 
frequently only partial success can be attained. Indeed, the success of double-blinding 
and analysis by lntention-to-treat hinge upon luccessf'ul randomisation. It 
investigators cannot conceal allocations up to the point of assignment, they would 
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have difficulty blinding after, and the concept underlying intention-to-treat analyses is 
simply the preservation of the randomised allocation. 
Considering how centrally important randomisation is to any assessment of the 
validity of a treatment comparison, it is surprising that authors and editors have not 
been more meticulous in publishing clear reports of the process used to assign 
participants to comparison groups. 
3.5.2 Treatment allocation in the obstetrics and gynaecology journals with a 
comparison to that in general medical journals 
~ 
A non-random method accountedl\5% of the 'randomised' trials published in the 
obstetrics and gynaecology journals. That rate is at the lower end of the range (5-
10%) found in earlier surveys of reports of'randomised' trials (Mosteller et al. 1980; 
Evans and Pollock 1984; Chalmers et al. 1986), but substantially higher than the rate 
of 1% found in Altman and Dore's (1990) more recent study of general medical 
journals. 
Blocking was reported in only 11 % of trials reported in the obstetrics and 
gynaecology journals as compared to 28% in the general journals, but the true rates 
are likely to be higher. The information on the size of the blocks used was missing 
in over a third of these reports in both types of journals. Stratification was mentioned 
explicitly much less frequently in the obstetrics and gynaecology journals (goAt) than 
in the general medical journal. (39%). However, in both type. of joumall, about balf 
of the reports in which stratification had been mentioned made no reference to 
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blocking. Although blocking had probably been used in a higher proportion than that, 
its use should have been stated explicitly because stratification is not effective unless 
blocking, or some form of restriction, has been used as well. The authors of only 
four trials reported simple randomisation, but a majority of the trials in which an 
approach had not been stated explicitly had probably used simple randomisation 
(Altman and Dore 1990). 
The method of generating random numbers was less well reported in the obstetrics 
and gynaecology than in the general journals. In only about a third of the reports in 
the obstetrics and gynaecology journals was it concluded that an acceptable approach 
had been used, as compared to almost half of the reports in the general journals. 
Moreover, those are generous estimates, since they include processes such as shuflled 
cards and tossed coins as adequate. Because those methods are subject to human 
perturbations in the production of allocation schedules and are not reproducible, they 
are certainly less than optimal (Mosteller et al, 1980), if not unacceptable (Meinert 
1986). Random number tables and computer random number generators are 
recommended not only for being reproducible, but also for being easier and faster. 
In the process of allocating treatments such that foreknowledge of the allocation is 
prevented, allocation concealment is generally more important than generation of the 
randomised assignments ~ ~ (Bradford Hill 1952; Chalmers et aI. 1987b), yet only 
52% of the reports in the obstetrics and gynaecology journals, and 56% of those in 
the general medical Journal., provided information adequate to useu that aspect of 
trial design and conduct Many of those stated approaches were judged to have been 
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inadequate, however, and even with those judged to have been adequate, many reports 
should have provided further important, clarifying information (see section 6.4.4). In 
sum, only 23% of the studies reported in the obstetrics and gynaecology journals as 
compared to 26% of the studies reported in the general journals appear to have used 
an adequate approach to allocation concealment. Overall, only 9% of the reports of 
trials published in the obstetrics and gynaecology jownals clearly stated that adequate 
methods of both random number generation and allocation concealment had been 
used. 
While descriptions of the process of treatment assignment were of generally poor 
quality in both the obstetrics and gynaecology and the general jownals, the specialty 
journals were, on average, somewhat less satisfactory. Remember, however, that the 
time frames for the assessments were different. The data from the general journals 
was collected from reports published 3 to 4 years earlier than those from the 
obstetrics and gynaecology journals. Some of the general journals, The Lancet for 
example, have instituted new statistical review procedures which would have likely 
produced more favourable results if new data had been collected concurrently with the 
obstetrics and gynaecology journal data collection. Thus, the actual disparity between 
these specialist and general journals is probably even greater than the disparities 
reported. 
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3.5.3 Descriptions of treatment allocation in the BJOG compared with those in 
the other three journals 
Reports of trials published in the BJOG were more informative than those in the 
other three obstetrics and gynaecology journals. Although the frequency of reports 
providing evidence that an acceptable approach to generating random numbers had 
been used was similar in the four journals, reports of trials published in the BJOG 
more frequently included information about the type of randomisation, and they were 
nearly 3 times more likely to report an adequate approach to allocation concealment 
than the other three journals combined. Furthermore, reports published in the BJOG 
were 3 times more likely than those published in the other three journals combined to 
have reported the use of statistical power calculations. Among the four journals, the 
overall methodological quality of reports published in the BJOG was highest, with 
those published in the two journals from the U.S. being similar and superior to reports 
published in the JOG. Editorial efforts similar to those made at the BJOG in the 
mid-1980s are now occurring at OG (Grimes 1991), and those too may result in 
improved quality of reports. 
Overall, the methodological quality of reports in the BJOG was commensurate with 
that found in reports published in the four general medical journals. Indeed, in 
important respects (such as allocation concealment and prior statistical power 
calculations) the quality of reports published in the BJOG matched or exceeded that 
found in the best of the four general medical journals. Much room for improvement, 
however, still remains in the BJOG. Some rather basic errors of commission and 
omission continued to be made. 
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3.5.4 The numbers of participants in the comparison groups were too often 
similar in trials that had used unrestricted randomisation 
Restricting randomisation to balance the numbers in comparison groups in a trial is 
useful not only to retain statistical power, but also to control for any time trends that 
may exist in treatment efficacy and outcome measurement during the course of the 
trial. It is essential if benefits from stratification are to be attained. Nevertheless, 
restriction can be thought of as primarily cosmetic in large trials. Simple, unrestricted 
randomisation will usually suffice if trials are sufficiently large to ensure a reasonable 
balance of numbers in the groups. Some discrepancy between the treatment group 
numbers will normally result, but this will not usually have an important effect on the 
power of the study (Altman and Dore 1990). 
The relative sizes of comparison groups in trials in which simple randomisation has 
been used should reflect random variation. In other words, some discrepancy between 
the numbers in the comparison groups is to be expected. The rmding that the 
reported sizes of the comparison groups tended to be much too similar, however, 
confumed the earlier finding from general journals. Not only were the similarities 
found very unlikely to be due to the play of chance, they were even more similar than 
those revealed in the earlier study. 
The strong tendency for the comparison groups to be of equal or similar sizes in these 
two studies may be explained by: (1) failure to report the use of blocking; (2) failure 
to report the usc or replacement randomisation; (3) failure to report the use or a 
restricted shuflled envelope method; (4) failure to report the use of a systematic 
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method of assignment, such as alternation or odd-even date; or (5) 'rectification' of an 
imbalance in sample sizes by non-random manipulation of assignments or data. 
Use of blocking would be the most palatable of those possible explanations, but it is 
unlikely to explain many cases since so few trials reported blocking, and, in 
particular, since the blocked trials yielded more disparate differences than the 
unblocked trials. Replacement randomisation would also be an acceptable 
explanation, but no evidence for its use was found. A less acceptable alternative 
would be that the restricted shuffle approach had been used (Mosteller et al. 1980). 
Only 5% of the trials that specified a type of randomisation used that method, 
however, so this seems an unlikely explanation for the similarity in the reported size 
of the comparison groups. A more likely explanation is the use of systematic 
allocation. Of the reports in which a method of generation was stated, 14% used this 
approach. Thus, the unidentified use of systematic allocation may explain at least 
some of the similarities in the numbers of participants assigned to the comparison 
groups. Unfortunately, that explanation is not reassuring since systematic allocation is 
both non-random and unlikely to be concealed. 
The last possibility, non-random manipulation of treatment groups, has serious 
implications because it is the most likely of the possible explanations to introduce 
selection bias into the comparisons made. Indirect evidence now exists from these 
journals and from the general medical journals that non-random manipulation may 
have sometimes occurred. Possibly some Investigator. beUeved that they would 
increase the credibility of their trial reports if they presented comparison groups of 
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equal size. Unfortunately for good science, but fortunately for those investigators, 
most readers probably shared their misconception. Paradoxically, the results of those 
possible manipulations have had exactly the opposite effect when analyzed in 
aggregate in this study. While these results clearly indicate that the set of trials 
supposedly using unrestricted randomisation are not what they purport to be, one 
cannot identify any particular trials as suspect, as some trials would be expected to 
achieve almost equal numbers simply by chance. 
3.5.S The percentage of statistically significant differences in baseline 
characteristics materialized as less than the expected level of 5% 
On strictly theoretical grounds, if randomisation is properly implemented, 
establishment of comparability at baseline is not necessary. Random assignment 
permits the use of probability theory to depict the extent to which any difference in 
outcome between treatment groups is likely to be due to chance. Although, in a 
particular study, the groups compared may never be perfectly balanced for important 
prognostic variables, randomisation makes it possible to ascribe a probability 
distribution to the difference in outcomes between the comparison groups, and a 
probability can then be assigned to the observed difference between them. The 
process of randomisation underlies significance testing, and that process is 
independent of prognostic factors, known or unknown (Fisher 1966). 
In practice, however, comparison of baseline characteristics in the trial groups is 
useful for at least two reasons. First, evidence that reasonable similarity in baseline 
characteristics has been achieved will tend to support a claim that randomisation has 
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been implemented correctly. Second, the point estimates of effects may be improved 
by statistical adjustment to take account of chance baseline imbalances in important 
prognostic variables, and it may also increase precision (Lavori et aI. 1983). 
Although comparisons of baseline characteristics were presented in a majority of the 
reports published in the obstetrics and gynaecology journals (84%), many of the 
reported comparisons were deficient. In reports in which at least one continuous 
variable (such as a mean or median) had been presented, 32% were either 
unaccompanied by measures of variability, or accompanied by a measure that was 
inappropriate (most frequently the standard error). A higher proportion (48%) of the 
reports published in the general medical journals were deficient in this respect 
An even more worrying deficiency, which was present in 61 % of the reports in the 
obstetrics and gynaecology journals and 58% of the reports in the general journals, 
was the inappropriate use of hypothesis tests to compare the distribution of baseline 
characteristics in the comparison groups. Using hypothesis tests to compare baseline 
characteristics in RCTs assesses the probability that the differences observed have 
occurred by chance, when, in properly randomised trials, it is known already that any 
differences observed 11m occurred by chance. As noted by Altman (1985) 
elsewhere, "Such a procedure is clearly absurd". Hypothesis tests are superfluous and 
their use in comparisons of baseline characteristics can mislead investigators and their 
readers. Rather, comparisons should be based on consideration of the prognostic 
strength of the variable. measured and the magnitude of any chance imbalances that 
have occurred (Altman 1985). 
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Although use of hypothesis tests inappropriately addresses the assessment of baseline 
imbalances in prognostic characteristics (Altman 1985), these tests might, in principle, 
be used by investigators who are concerned that randomisation may not have been 
executed effectively in their studies (Altman 1985). Sometimes gross imbalances, 
quite incompatible with random variation, are revealed in this way (Keirse 1988). 
Finding several statistically significant differences between the comparison groups 
may suggest that randomisation has not been achieved; but use of tests in this way 
will often pose substantial problems of interpretation. 
Concern that randomisation may not have been executed correctly seems an unlikely 
explanation for the use of hypothesis tests by the authors of the 61 % of reports in 
which test results were presented: only 2% of the tests reported were statistically 
significant at the 5% level, a discrepancy from expectation which is unlikely to reflect 
chance. That observed frequency of statistically significant test results in the 
obstetrics and gynaecology journals is more extreme in its departure from the 
expected than the value of 4% reported by Altman and Dore (1990) from general 
journals. 
A plausible explanation for these discrepancies is that, when comparing baseline 
characteristics using hypothesis tests, investigators may decide not to report a 
statistically significant result, believing that by withholding that information they will 
increase the credibility of their reports. In fact, the opposite has occurred with the 
aggregate analysis in this study. Having too fow statistically significant results hu 
hurt the credibility of these trials. Investigators should report baseline comparisons on 
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important prognostic variables whether they are statistically significantly different or 
not. Clearly, not only are hypothesis tests superfluous and potentially misleading, 
they can be positively harmful if they lead investigators to suppress any baseline 
imbalances. 
3.5.6 Conclusions 
None of the findings reported in this chapter are particularly reassuring. Although 
failure to report steps to reduce bias does not constitute direct evidence that those 
steps have not been taken, at least one study, in which clarification was sought from 
the authors of reports, has shown that inadequate reporting usually reflects inadequate 
methodology (Liberati et al. 1986). Thus, while reporting clearly must be improved, 
the deficiencies in the design and conduct of trials must also be urgently addressed. 
Although, as predicted, descriptions of the process of generating and applying 
treatment assignments in reports of trials published in obstetrics and gynaecology 
journals were of somewhat poorer quality than those published in general journals, the 
standard of reporting in both samples leaves a great deal to be desired. Although the 
quality of reports of trials published in the BJOG was indeed better than that of those 
published in the other three obstetric and gynaecology journals (and of comparable 
quality to those in the best general medical journals), considerable scope for 
improvement exists. 
It was confirmed that the numbers of participants in the comparison groups of trials 
which have apparently used simple randomisation were too often too similar, and that 
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the observed percentage of statistically significant differences in characteristics 
measured at baseline was less than the expected value of 5%. Those are disturbing 
findings in that they suggest the occurrence of some non-random manipulations of 
comparison groups and some selective reporting of baseline comparisons. 
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Chapter 4 
4. The Association Between Methodological Quality 
and Treatment Effects in Controlled Trials: An 
Analysis of 250 Trials from 33 Meta-Analyses 
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4.1 Summary 
4.1.1 Objective. Most reports of randomised controlled trials contain inadequate 
methodological descriptions. The primary aim was to explore the association between 
those inadequate descriptions and estimates of treatment effects. 
4.1.2 Methods. The methodological quality of the trials was assessed on major 
dimensions and then the associations between those assessments and estimated 
treatment effects were analyzed. The analysis used 250 trials from 33 meta-analyses 
encompassing 62,091 participants and employed multiple logistic regression models. 
4.1.3 Results. Compared with trials in which authors reported adequately concealed 
treatment allocation, trials in which authors reported inadequately or unclearly 
concealed allocation yielded larger estimates of treatment effects (p<0.001). Odds 
ratios were distorted by 41% or 33%, respectively. Trials in which participants were 
excluded after randomisation were not, however, associated with larger treatment 
effects, but that appears to be due to incomplete reporting rather than to the 
unimportance of adequately handling exclusions. Lack of double-blinding in trials 
was also associated with larger treatment effects (p=O.OI), albeit at a lower strength 
than the lack of adequate measures to conceal assignment. Furthermore, inadequately 
concealed trials displayed greater variability (heterogeneity) compared with the 
adequately concealed trials. 
4.1.4 Conclusions. Inadequate methodological approaches in controlled trials, 
particularly those reflecting inadequate or unclear allocation concealment, were 
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associated with reported larger treatment benefits. Those associations likely represent 
bias. To be successful at minimising bias, investigators must properly design and 
meticulously execute their trials. 
4.2 Introduction 
When conducting a controlled trial, properly implemented randomisation avoids 
selection biases. Yet, as shown in Chapter 3, many trials in journals of obstetrics and 
gynaecology may be inadequately executed. Are those trials associated with biased 
estimates of treatment effects? Presumably, investigators could introduce bias into 
inadequately executed trials, but meagre quantitative evidence supports that 
presumption. 
While only meagre evidence is available on proper versus improper randomisation, 
more documentation supports the notion that randomised as compared with non-
randomised comparisons reduce bias (Chalmers et al 1977; Pocock 1979; Sacks et al 
1982; Chalmers et al 1983; Miller et al 1989; Colditz et al 1989). In those analyses, 
the trend is for the non-randomised trials to report larger estimates of treatment 
effects than do the randomised trials. That poorly-executed versus well-executed 
'randomised' trials would follow the same trend seems logical. 
Indeed, the results of one such analysis did follow that same trend (Chalmers et al. 
1983). Apparently, bias may be introduced into trials labelled as 'randomised' if 
investigators do not take precautions to conceal treatment allocation schedules from 
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those responsible for recruiting and entering participants. As reviewed in section 
2.4.2, an analysis published in 1983 found that trials in which the treatment allocation 
schedule had been inadequately concealed yielded larger estimates of treatment effects 
than trials in which allocation had been adequately concealed (Chalmers et al. 1983). 
However, while the larger estimates of treatment effects may have reflected biases 
resulting from foreknowledge of treatment allocation, they also may have reflected the 
confounding effects of the different treatments represented among the two categories 
of trials (Gillman and Runyan 1984). 
In an attempt to address that potential source of confounding, a later study restricted 
an analysis to trials that had evaluated comparable treatments in terms of similar 
outcome measures (Emerson et al. 1990). They did not, however, detect a 
relationship. They also suspected that low quality trials might produce bias in both 
directions thereby causing greater variability in estimates of treatment effects. Again, 
they did not detect evidence of such. 
As reviewed in section 2.4.2, the authors of the Emerson et aI. (1990) study, rather 
than concentrating only on adequacy of the concealment of allocation schedules, 
sought a relationship between 'quality scores' intended to characterize the overall 
methodological quality of each trial (Chalmers et al. 1981) and estimates of treatment 
effects. That and other methodological aspects of their approach may have 
handicapped their ability to accurately assess the relationship. 
Using a database of systematic reviews of controlled trials in pregnancy and childbirth 
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(Enkin et al. 1993), I conducted a retrospective observational study to explore the 
associations between estimates of treatment effects and methodological approaches 
intended to control bias. The hypotheses tested were that estimates of treatment 
effects would be larger in trials in which (i) inadequate measures had been taken to 
conceal treatment allocation; (ii) some participants allocated had been excluded; (iii) 
measures had not been taken to implement double-blinding; or (iv) inadequate 
measures had been taken to generate the allocation schedule, given that allocation had 
been adequately concealed. In addition, analyses included whether estimates of 
treatment effects varied more in trials in which treatment allocation schedules had not 
been adequately concealed. 
4.3 Methods 
4.3.1 Derivation of study material 
The systematic reviews of controlled trials used in this analysis have been published 
in printed and electronic forms by the Pregnancy and Childbirth Group of the 
Cochrane Collaboration (Chalmers et al. 1989; Chalmers 1992; Enkin et ale 1993). 
Published and unpublished primary trials potentially relevant for inclusion in the 
reviews were sought and entered in a register, the Oxford Database of Perinatal Trials, 
using methods that have been described in detail elsewhere (Chalmers et ale 1986; 
Hetherington et al. 1990; Chalmers et ale 1989). Broad entry criteria were used 
during this primary phase of data collection for the reviews. Trials were eligible for 
inclusion in the register if some attempt had apparently been made to create unbiased 
comparison groups, either by randomisation, or by using a method such as alternation 
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in a consecutive series, case record number, or date of birth. 
The methods used in preparing the reviews have been described in detail elsewhere 
(Chalmers et aI. 1989). Reviewers were required to assess the quality of possibly 
relevant trials using a hierarchy of three dimensions relevant to the control of bias --
concealment of treatment allocation schedule, avoidance of exclusions after trial entry, 
and blinding of outcome assessment. Because the trials incorporated in most of these 
reviews varied in quality, the result of each trial was plotted graphically in a hierarchy 
reflecting its quality assessment. In that way, both those preparing the reviews and 
those reading them could be alerted to patterns of results which might reflect the 
influence of bias (Chalmers et al. 1989). The present analysis explores that variation 
in methodological quality among component trials in systematic reviews. 
The database contained a total of more than 500 systematic reviews (Enkin et al. 
1993), but about 60% comprised just one or two trials. An appropriate, manageable 
sample of reviews for this analysis was derived as follows. First, an initial subset of 
82 reviews was selected on the basis of the following criteria: each had used meta-
analysis to produce a quantitative synthesis of at least 5 trials, and each had a total of 
at least 25 outcome events among the trial control groups contributing to the review. 
Second, to ensure that data from a particular component trial would contribute only 
once to the main analysis, all meta-analyses to which each component trial had 
contributed were identified, and only the meta-analysis with the most homogeneous 
grouping of interventions was retained for inclusion in the analysis. For example, a 
meta-analysis incorporating a specific class of antibiotics given for prophylaxis with 
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caesarean delivery would be included in preference to a meta-analysis which had 
included trials of any antibiotic used in that way. With only minor levels of overlap 
between two meta-analyses, an overlapping trial was deleted from one of them. That 
happened with only 6 trials; a random number table determined the deletions. And 
third, the meta-analyses included in the analysis had to comprise at least one 
component trial with adequate concealment (see below) of the treatment allocation 
schedule and at least one trial without. 
Of the meta-analyses not used in this study, most exclusions were because of 
substantial overlap with another meta-analysis, or because no trials had reported 
adequate allocation concealment. Two meta-analyses were excluded, however, 
because all of the component trials had used adequate approaches to allocation 
concealment. 
After that selection process had been applied, 33 meta-analyses remained for analysis. 
Appendix 4.1 provides a brief description of each. They related to care during 
pregnancy (2), preterm labour and delivery (4), induction of labour (7), labour and 
delivery (6), prophylactic antibiotics for caesarean delivery (7), the puerperium (3), 
and the neonatal period (4). Unpublished trials and trials reported in languages other 
than English were dropped from this analysis because of difficulty in evaluating the 
necessary information. These 33 meta-analyses included data from 250 primary trials 
involving a total of 62,091 participants with 12,030 outcome events measured. The 
trials included were published between 19~~ and 1992. or the 2~0 trial .. 10% were 
published from 1955-1969, 18% from 1970-1979, 61% from 1980-1989, and 11% 
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from 1990-1992. The overall effect in all of the meta-analyses suggested that the 
experimental interventions were more effective than the control interventions in 
preventing adverse outcomes, thus yielding summary odds ratios of less than 1.0. 
4.3.2 Assessment of trial quality 
7S 
Unfamiliar with the topics, journals, and investigators covered, I evaluated each of the 
250 published trial reports contributing to the 33 selected meta-analyses. The trial 
quality was assessed using the same dimensions that had been used by the reviewers 
in the Cochrane Pregnancy and Childbirth Group (Chalmers et al. 1989), apart from 
also assessing the adequacy of sequence generation. For the current analysis, 
however, assessments entailed special efforts to ensure consistency of quality 
assessments by using a single observer with a more detailed classification scheme and 
data abstraction instrument, and by blinding the assessment process to the results of 
the trials. Blinding was achieved in assessing the descriptions of randomisation and 
blinding in the articles, because authors embedded those descriptions in the methods 
sections. Blinding assessments of exclusions after trial entry, however, posed greater 
difficulties, because authors frequently addressed those descriptions in the results 
sections. Trials were assessed on the following four major dimensions: 
A) Concealment of treatment allocation schedule Trials were divided into three 
groups. 
• Adequately concealed trials, which were the referent group, deemed to 
have taken adoquate approachel to allocation concealment (central 
randomisation; numbered or coded bottles or containers; drugs prepared by 
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the pharmacy; serially numbere~ opaque, sealed envelopes; or other 
description that contained elements convincing of concealment). 
• Inadequately concealed trials in which concealment was clearly 
inadequate (such as alternation or reference to case record numbers or to 
dates of birth) . 
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• Unclearly concealed trials in which the authors either did not report an 
allocation concealment approach at all or reported an approach that did not 
fall into one of the above categories. A majority of the trials in this group 
probably had randomised allocation schedules, but had inadequate 
concealment. On the other han~ a few probably had randomised allocation 
schedules with adequate concealment and a few others probably had used 
systematic, unconcealed allocation. 
B) Inclusion of all randomised participants A referent group of trials that 
reported, or gave the impression, that no exclusions had taken place (vast majority 
not explicit), and a second group of trials that reported having made exclusions. The 
reasons for exclusions, when reported, included protocol deviations, withdrawals, 
drop-outs, and losses to followup. 
C) Double-blinding A referent group of trials that reported being double-blinded, 
and a second group that did not report as such, deemed not double-blinded. Only 
meagre information was made available on the approaches used for double-blinding, 
so the classification was based necessarily on whether the reports purported to be of 
double-blind trials. 
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D) Generation of allocation sequences A referent group of adequate sequence 
generation trials which reported adequate approaches (random number tables, 
computer random number generators, coin tossing, or shuffling), and a second group 
which did not report one of the adequate approaches, those with inadequate sequence 
generation. This dimension was analyzed only in the subset of 79 trials that had 
reported adequate allocation concealment. That analytical approach makes sense 
because having a randomised (unpredictable) sequence would make little difference 
without adequate concealment. Yet in trials with adequate concealment, particularly 
those where group assignment becomes known after allocation (such as in unblinded 
trials), a randomised sequence may become important. 
The data were entered interactively into an EPI-INFO questionnaire with on-line 
editing, skip-pattern, and logic-checking capability (Dean et al. 1990). Basic 
tabulations were done using EPI-INFO. To examine the reproducibility of items on 
the questionnaire, Douglas O. Altman (Head, Medical Statistics Laboratory, Imperial 
Cancer Research Fund) reassessed a sample (selected with the EPI-INFO computer 
random number generator) of 10 trials blinded to the initial assessments. Information 
on sequence generation, allocation concealment, blinding, and numbers of participants 
randomised and analyzed revealed no notable inconsistencies with the initial 
assessments. Information on whether a trial used 'intent-to-treat' principles, however, 
revealed some inconsistencies, largely because the reports forced that assessment to be 
made subjectively by not providing explicit information. Thus, assessments of intent-
to-treat were not analyzed. 
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A recapitulation of two concepts addressed in section 2.3 may be helpful. Allocation 
concealment can always be implemented, seeks to prevent selection bias, and protects 
the assignment sequence before and until allocation. On the other hand, double-
blinding cannot always be implemented, seeks to prevent ascertainment bias, and 
protects the assignment sequence after allocation. 
4.3.3 Statistical methods 
The intention was to examine, across all 33 meta-analyses, associations between the 
indicators of trial quality described above and estimates of treatment effects (odds 
ratios). Multiple logistic regression models were used, including a binary variable for 
treatment group (experimental or control), indicator variables to control for the effects 
of each of the 250 trials, and terms for the 'meta-analysis-by-treatment group' 
interaction (to control for the different overall odds ratios for the treatment effects in 
the 33 meta-analyses). While all these terms needed to be accounted for in the 
analysis, estimates of the parameters did not need to be provided. The indicator 
variables for the different meta-analyses were not included in the models because they 
were completely confounded with the variables representing the trials. 
The effects of all the methodological quality measures were measured at the trial 
level. Their main effects were, however, completely confounded with variables 
representing the trials, which were already in the basic model. The terms for 'quality 
measure-by-treatment' interaction addressed the main question of interest, namely 'On 
average, do triab Judged to have been methodologically Inferior yield dHrerent 
odds ratios from trials assiped to the relevant best (referent) category?' Since 
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all of the treatment effects in these trials were coded in the same direction, a relative 
odds of less than 1.0 for one of these interaction terms would mean that trials that 
were methodologically inferior had yielded larger estimates of treatment effects, on 
average, compared to the referent group. Conversely, a relative odds of larger than 
1.0 would indicate association with smaller treatment effects or perhaps even 
treatment risks. 
After analysing inadequately concealed trials in the initial model, they were excluded 
from further analyses of associations with treatment effects. The further analyses 
included adding additional terms to the models and the data would have become quite 
thin with only 21 inadequately concealed trials. Moreover, including them in further 
analyses makes little theoretical sense. For example, analysing the impact of double-
blinding in inadequately concealed trials would be unjustified since double-blinding 
would likely be impossible under such circumstances. Furthermore, given the initial 
results, the determination ensued that the most important analyses thereafter should 
focus on the unclearly and adequately concealed trials. 
To analyze the variability (heterogeneity) of the three allocation concealment groups, 
a separate model was fitted to each of those independent groups of trials. Each model 
included a binary variable for treatment, indicator variables for the individual trials, 
and interaction terms for 'meta-analysis-by-treatment.' The deviances derived from 
those models are approximately chi-squared distributed. Then the remaining 
heterogeneity in the unclearly and inadequately concealed groups were separately 
compared to the adequately concealed group, using F -ratio tests. 
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GLIM 4 (Francis et al. 1993) was used for modelling, using the 'eliminate' command 
for the trial parameters. The deviances and degrees of freedom (df) for the models 
appear in Tables 4.2 and 4.3. The changes in deviance associated with adding term(s) 
to models have an approximately chi-square distribution, with degrees of freedom 
equal to the difference in degrees of freedom between the two models. 
A model yielding a greater deviance than its degrees of freedom indicates 
heterogeneity (also referred to as 'overdispersion' or 'extra-binomial variation'). For 
one model (B3/C4) in the analysis, a simple adjustment to the scale parameter took 
rough account of overdispersion for estimating standard errors (Aitkin et al. 1989). 
That adjustment yielded a model with a deviance equal to its degrees of freedom. 
Separate multiple logistic regression analyses were also performed on the trials in 
each of the 33 meta-analyses. The basic model for these included parameters for 
trials and treatment. The primary analytical variables of interest were the terms 
describing the interactions between allocation concealment and treatment. 
4.4 Results 
4.4.1 Characteristics of the 250 trials 
Steps taken to conceal treatment allocation schedules were adequate in 79 trials, 
unclear in 150, and inadequate in 21. Overall, 63% did not report any exclusions, but 
the reported quality of the allocation concealment was inversely related to the 
proportion without exclusions (Table 4.1). The trials that reported using adequately 
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concealed allocation were the most likely to have reported excluding participants 
whereas the trials which reported using inadequately concealed allocation were the 
least likely. The unclearly concealed trials reported exclusions at an intermediate 
level between those two. Double-blinding and having used adequate sequence 
generation, however, were much more common in the adequately concealed trials than 
in the other groups (Table 4.1). 
4.4.2 Concealment of treatment allocation schedules and estimates of 
treatment effects 
Trials with inadequate or unclear concealment measures yielded more pronounced 
estimates of treatment effects than trials that had taken adequate measures to conceal 
allocation schedules (p<0.001; Model A2; Table 4.2). Excluding from analysis 
inadequately concealed trials, the association for unclearly concealed trials was 
statistically significant (p<0.001; chi-squared=48.6, 1 d.f.; Model B2; Table 4.2) and 
remained so after accounting for the effects of exclusions and double-blinding (Model 
B3; Table 4.2). The relative odds was 0.70, which means that the odds ratios in the 
unclearly concealed trials were, on average, 30% lower than in the adequately 
concealed trials, i.e., estimating larger treatment effects. 
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Table 4.1 
No exclusions, double-blinding, and allocation schedule generation 
by the level of allocation concealment for 250 controlled trials 
Authors Adequately Unclearly Inadequately All 
reported: concealed concealed concealed trials 
No apparent 
exclusions 53% 67% 76% 63% 
Double-blinding 
73% 39% 14% 48% 
Adequate 
generation of 29% 15% 0% 18% 
allocation 
schedule 
Total 100% 100% 100% 100% [N] [79] [150] [21] [250] 
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Table 4.2 
Association between Judgement of concealment of treatment allocation 
and estimates of treatment etTects 
Trials 
Level of concealment of Relative odds Deviance Modell treatment allocation 
included [interaction terms]2 [95% eQ [d.f.] 
Al Base model 492.09 - [217] 
Adequate 1.00 
All trials Unclear 0.67 
[n = 250] A2 [0.60 - 0.75] 434.18 [215] 
Inadequate 0.59 
[0.48 - 0.73] 
Bl Base model 381.69 - [196] 
Adequate 1.00 
Adequately B2 Unclear 0.67 333.13 
and [0.60 - 0.75] [195] 
unclearly 
concealed 
trials Adequate 1.00 
[n = 229] 
B3 Unclear 0.70 W.'! [0.62 - I.", (WJ 
[adjustedl' 
IMultiplc logistic regression models include a binary variable for treatment, indicator variables 
for the trials, and meta-analysis by treatment interaction terms 
2All terma involve an int.rlQtion with tr.atment effegt 
'Model includes the exclusion and not-double-blinding by treatment interaction terms which 
adjusts for their effects in this analysis 
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The results of the 33 separate logistic regression analyses were consistent with the 
aggregated modelling results. The direction of the effects for the unclearly concealed 
trials were toward larger estimates of treatment effects in 27 and smaller in 6. While 
supportive of the overall trend, this might indicate that the effect of concealment may 
not have been the same in every meta-analysis. Indeed, an interaction term for 
'unclearly concealed-by-treatment-by-meta-analysis' was statistically significant 
(p=O.Ol; chi-squared=53.7; 32 d.f.), meaning that the effect of unclearly concealed 
trials on estimation of treatment effects varied by more than chance among the meta-
analyses. 
4.4.3 Exclusions after allocation and estimates of treatment effects 
Accounting for allocation concealment, trials that excluded participants yielded 
estimates of treatment effects that, on average, were smaller than those derived from 
trials that had not excluded any participants. However, this association was not 
statistically significant (p=O.21, chi-squared=1.54, 1 d.f.; Model C2; Table 4.3), and 
taking double-blinding into account hardly affected its strength (Model C4; Table 
4.3). 
4.4.4 Double-blinding and estimates of treatment effects 
Accounting for allocation concealment, trials that were not double-blinded yielded 
estimates of treatment effects that, on average, were larger than those derived from 
trials that were double-blinded (p=O.OI; chi-squared=6.S0; 1 d.f.; Model C3; Table 
4.3). Controlling for exclusions after allocation did not influence the strength of this 
association (Model C4). 
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Table 4.3 
Association between assessments of methodological elements to control 
bias after randomisation and estimates of treatment effects 
Trials Modell Methodological element Relative odds Deviance 
included [interaction terms)2 [95% CI) (d.t) 
Cl Base 333.13 
- [195) 
No exclusions 1.00 
C2 Exclusions 1.0S 331.59 
[0.96 - 1.23) [194) 
Adequately Double-blinded 1.00 
and 326.63 
unclearly C3 Not double-blinded 0.S2 (194) 
concealed [0.71 - 0.96) 
trials 
[n=229) No exclusions 1.00 
Exclusions 1.07 
(0.94 - 1.21) 
C4 325.61 
Dou ble-blinded 1.00 (193) 
Not double-blinded 0.S3 
[0.72 - 0.96) 
1 All models include a binary variable for treatment, indicator variables for the trials, meta-
analysis by treatment interaction terma, and an allocation concealment by treatment interaction 
term. 
2A11 terms involve an interaction with the treatment effect. 
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4.4.5 Generation of allocation sequence and estimates of treatment effects 
In those 79 trials that had used adequately concealed allocation, trials with inadequate 
sequence generation yielded larger estimates of treatment benefits, on average, than 
trials with adequate sequence generation (relative odds of 0.75; 95% CI of 0.55 -
1.02; p=O.07). That association was of marginal statistical significance, however. 
4.4.6 Allowance for overdispersion 
Because statistically significant heterogeneity remained in the model represented in B3 
or C4 (Table 4.2, Table 4.3), a separate analysis allowed for overdispersion. The 
point estimates remained the same, but the 95% confidence intervals for the terms 
widened slightly: unclearly concealed (0.60-0.82); exclusions (0.91-1.25); and not 
double-blinded (0.68-1.01). 
4.4.7 Heterogeneity 
Odds ratios derived from trials that had used inadequately concealed allocation yielded 
statistically significantly more variability (heterogeneity) than those from adequately 
concealed trials (Table 4.4). Although the unclearly concealed trials also yielded 
greater heterogeneity compared with the adequately concealed trials, it was not 
statistically significantly greater. 
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Table 4.4 
Examination of the variability (heterogeneity) of the unclearly and the inadequately 
concealed trials relative to the adequately concealed trials 
Concealment Model· Deviancez F-ratio for comparison to the adequately concealed trials P-value Status [N) [d.t) [df., dfz) 
Adequate 66.32 [79) D - -(46) 
Unclear 213.10 F=1.16 [150) E [117) [117,46] 0.19 
Inadequate 43.07 F=4.17 [11] F (7) [7,46] 0.001 
1 Linear logistic regression models include a binary variable for treatment. indicator variables 
for the trials. and meta-analysis by treatment interaction terms: separate models for each set of 
trials 
1 Indicating the residual heterogeneity 
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4.5 Discussion 
4.5.1 General findings 
Comparisons of different forms of health interventions 'can be misleading unless 
investigators take precautions to ensure that their study contains unbiased comparison 
groups with respect to prognosis. Random allocation to alternative forms of 
interventions remains the only way of controlling for selection biases. That 
characterizes randomisation's only unique strength. That strength, however, becomes 
of crucial importance in the common circumstances where the treatment effects may 
be of comparable magnitude to the biases that plague most non-randomised 
comparisons of alternative forms of health care. 
In view of the central importance of randomisation for achieving unbiased 
comparisons, it is surprising that authors so often inadequately detail the steps taken 
to assign participants to comparison groups in trials (Mosteller 1980; DerSimonian et 
al. 1982; Altman and Dore 1990), including authors in the medical specialty 
represented in this analysis (Chapter 3). If randomisation prevents bias as suggested, 
trials that have failed to report adequate approaches to ensuring proper randomisation 
should yield systematically different estimates of treatment effects to those derived 
from trials that have apparently used adequate approaches. That proposition has been 
supported by the analyses in this chapter. Specifically, these analyses have confmned 
the prior hypothesis that, on average, trials that had not reported adequate measures 
for allocation concealment yielded estimates of treatment effects that were larger than 
those from trials that had used adequate approaches to concealment. In addition, 
these analyses have indicated that estimates of treatment effects were somewhat larger 
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in trials that had not reported double-blinding. 
4.5.2 Concealment of treatment allocation and estimates of treatment effects 
Trials that reported inadequate concealment methods yielded estimates of odds ratios 
that were distorted by an average of 41 % and trials that reported unclear concealment 
were distorted by an average of 30% (when adjusted), compared with estimates of 
odds ratios derived from trials which had apparently taken adequate steps to conceal 
treatment allocation. Those estimated distortions in odds ratios should not be 
interpreted as meaning that the distortions in relative risks would be of a similar 
magnitude. The proportion of outcome events in the control groups of the trials 
studied was almost 20% overall, and ranged from less than 1 % to over 90%. The 
odds ratio poorly estimates relative risk with proportions over 5%-10%, and gives 
more divergent estimates as proportions move towards 90%. Thus, a distortion of 
30% in odds ratios may translate, for example, to a distortion of only 10%-20% in 
relative risks. Nevertheless, biases of that magnitude seem considerable and clearly 
unacceptable. 
The effect of unclearly concealed trials on estimation of treatment effects varied by 
more than chance among the meta-analyses. Therefore, while a distortion of 30% in 
odds ratios for the unclearly concealed trials appropriately estimates the average 
association, it should not be interpreted as representing all the meta-analyses. In 
addition, that odds ratios yielded by inadequately concealed trials were more variable 
(heterogeneous) than those derived from trials with adequate concealment further 
illustrates that indeed inadequately concealed trials may unreliably protect against 
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bias. 
The associations found between the adequacy of allocation concealment and estimates 
of treatment effects probably reflect selection biases. Admittedly, poorly executed 
trials cannot be confmned as further from the truth than well executed trials since 
'truth' eludes recognition. Nevertheless, these results support the primary hypothesis 
and strongly suggest the presence of bias. 
Inadequate concealment of allocation schedules can lead to introduction of bias in 
many ways, sometimes as the result of deliberate subversions, sometimes as the net 
effect of subconscious actions. For example, if those responsible for admitting 
participants to trials have foreknowledge of treatment allocations, they may channel 
participants with a better prognosis to the experimental group and those with a poorer 
prognosis to the control group, or vice versa. That could easily be accomplished 
either by delaying a participant's entry into the trial until the next desired allocation 
appears, or by excluding eligible participants from the trial, or by encouraging them 
to refuse entry. Without allocation concealment, biases in both directions become 
possible, although the clear tendency identified in this study pointed towards larger 
treatment effects. 
Inadequate allocation concealment may also be a surrogate measure for the quality of 
other aspects of trial design and execution, such as blinding and handling of 
exclusions. The magnitude of the associations observed may thus also reflect biases 
other than selection biases at the point of treatment allocation. 
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In any case, however, the results from this chapter support the policy decision taken 
by one journal (Altman 1991b) not to publish reports of trials in which foreknowledge 
of treatment allocation is obviously possible, such as trials which have used 
alternation, case record numbers, or open lists of random numbers for allocation. 
These fmdings also emphasise the importance both of securing adequate allocation 
concealment in controlled trials, and of ensuring that authors and journal editors 
publish reports that make those aspects of trial design explicit. 
4.5.3 Exclusions after allocation and estimates of treatment effects 
Contrary to the prior hypothesis, trials that reported excluding participants after 
randomisation did not yield inflated estimates of treatment effects compared with 
trials in which there had apparently been no exclusions. Indeed, if anything, trials 
with reported exclusions yielded more modest estimates of treatment effects than other 
trials. That unexpected fmding could be the result of some authors inappropriately 
reporting that they had randomised the same number of participants as they had 
analyzed, even though some randomised participants had actually been excluded. 
The observed results on exclusions probably reflect incomplete reporting. That 
interpretation receives support from the paradoxical fmding that trials using 
adequately concealed allocation were the most likely to have reported excluding 
participants and that trials using inadequately concealed allocation were the least 
likely (Table 4.1). Few of the trials reporting no apparent exclusions explicitly stated 
that no exelusionl had taken place. 
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Gmzsche (1989b) has previously detected non-reporting of exclusions in two separate 
published trials; he speculated that articles in which the issue of exclusions after 
randomisation has not been addressed explicitly may be less reliable than those in 
which it has been. We found that authors often omit explicit information about 
exclusions, and we failed to detect any association between our classification of trials 
using the information available on exclusions and any differential effects of treatment 
That suggests that information on exclusions may currently have little value in 
assessing trial quality from published information. 
Investigators must be urged to report accurately the number of exclusions and, if none 
took place, to state so explicitly. They must also explicitly state their approach to the 
analysis, primarily whether they performed an intent-to-treat analysis. The ultimate 
users of RCTs, including in particular those performing systematic reviews, should be 
aware of the potentially misleading information provided on exclusions in currently 
published trials. Minimising exclusions and implementing an intent-to-treat analysis 
are likely to reduce bias, but available articles appear to report too incompletely to 
support a reliable examination of our hypothesis on this issue. 
4.5.4 Double-blinding and estimates of treatment erreds 
Trials for which no double-blinding was reported yielded estimates of odds ratios that 
were inflated by 17%, on average, compared with trials that reported having used 
double-blinding. Trials that reported double-blinding usually provided little, if any, 
information on the methods used. Consequently, some trials claiming to be double-
blind may not have been, and that measurement error could have been reflected in an 
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underestimate of the effect of not double-blinding. On the other hand, much of the 
effort to double-blind in these trials may have gone into concealing randomisation. 
Thus that could have led to a countervailing overestimate of the independent effect of 
not double-blinding. Whatever the net effects, blinding is clearly of far greater 
importance to minimizing bias for some outcomes than for others. 
4.5.5 Generation of allocation sequence and estimates of treatment effects 
In the 79 trials that had used adequate allocation concealment, trials that did not 
report an adequate sequence generation approach, presumably making prediction of 
the next allocation easy, found larger treatment effects. The confidence interval for 
the relative odds, however, just included 1.0. That rmding suggests that an 
unpredictable sequence should help to protect against bias if adequate allocation 
concealment is used. One could further speculate that the benefit gained from 
unpredictability would be particularly important when blinding is not instituted. The 
preparation of an unpredictable sequence could be quite useless if allocation was 
inadequately concealed. Therefore, given adequate allocation concealment, this result 
implies the importance of randomly generated, unpredictable allocation sequences. 
4.5.6 OverdispersioD 
Even using the wider confidence intervals based on the adjustment for overdispersion, 
the interpretation of the results remained essentially unchanged. Ideally, a random 
effects model, in which the treatment effect is assumed to vary randomly among 
trial., would be molt appropriato to addre •• ovordilpOnioD. Howovor. diffigulty in 
identifying a software package that handles both random effects and the requisite 
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large number of parameters in these models led to the use of an approximate 
adjustment (Aitken et al. 1989), in which the variance of each binomial response is 
assumed to be inflated by a constant factor ( the "scale parameter") chosen so that the 
deviance is equated to the degrees of freedom. It is unclear how accurate this 
approximate adjustment is likely to be in the current application, since a random 
effects model for the treatment effect, and the variable sample sizes of the trials, 
would imply a more complex variance structure. Nevertheless, the adjustment 
suggests that the results for allocation concealment would likely remain highly 
statistically significant regardless of the approach used, while some caution is 
advisable in interpreting the results for double-blinding. 
4.5.7 Test for comparative heterogeneity 
Odds ratios yielded by inadequately concealed trials were more heterogeneous than 
those derived from trials with adequate concealment To compare the heterogeneity 
between those two groups, the specified F -tests were used. These tests depend on the 
validity of the simple overdispersion model referred to in Section 4.5.6, and so should 
be regarded as approximate. Furthermore, theoretical considerations suggest that the 
apparent excess variability among inadequately concealed trials might be explained 
away if these trials had larger sample sizes on average. In fact, however, average 
sample size was smaller in the inadequately concealed trials than in the adequately 
concealed trials (93 compared with 203). That suggests that the greater mean 
deviance among inadequately concealed trials genuinely reflects greater heterogeneity 
of treatment effects among those trials. 
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4.5.8 Consideration of results in the light of previous resear<:h 
These results are consistent with the fmdings of Chalmers et ale (1983). Whereas 
their results may have been attributable to confounding by type of treatment, these 
results cannot be explained in that way because the analysis accounted for the effects 
of the 33 meta-analyses, each of which investigated similar treatments and similar 
outcome measures. 
Emerson et ale (1990), however, did not fmd a statistically significant association 
between methodological quality and treatment effects. Their fmdings do not 
necessarily conflict with the fmdings in this chapter for at least four reasons. First, 
and most important, the authors used a measure of quality (Chalmers et ale 1981) that 
quantifies many aspects of trial design and analysis, some of which were unlikely to 
be related to bias. Second, their inclusion of both study size and their measure of 
quality as explanatory variables in their model could have obscured the effects of 
quality relating to bias because study size correlated with quality score. Third, their 
statistical model may have been less sensitive since a logistic regression package able 
to handle the requisite number of parameters probably has only recently become 
available. Fourth, the trials used in their analysis may have been less heterogeneous 
in terms of quality than those included in this analysis, thus reducing the likelihood 
that they would have detected any associations that existed. 
4.5.9 Conclusions 
Some methods used to control biases in trials cannot always be implemented. For 
example, investigators cannot always blind participants, care-providers, and assessors 
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or include every randomised participant in all of the primary analyses of all the 
outcomes measured. By contrast, investigators should a/ways be able to conceal 
treatment allocation schedules so that proper random allocation can be assured. That 
not only addresses selection bias before treatment begins, but also serves as a 
prerequisite for the success of other measures (such as blinding and 'intention-to-treat' 
analyses) taken to control assessment and exclusion biases. 
Preventing foreknowledge of treatment allocation by effective concealment of 
allocation schedules emerges from the analyses as crucially important to protecting 
against bias. Without proper application of measures to achieve concealment, the 
whole point of randomisation vanishes. The results in this chapter support the 
comment of Mosteller and his colleagues (1980): "When the randomization leaks, the 
trial's guarantee of lack of bias runs down the drain". 
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Appendix 4.1 
Description of the interventions and outcome measures in the 
33 meta-analyses by general topical area 
General topical area Intervention in the meta-analysis Outcome measure 
Routine iron administration in pregnancy Hb < IO-IO.S g1dl at 36-40 wks. 
Pregnancy 
Baby weight <Sth <lOth Antiplatelet agents for IUGR and pre-eclampsia 
centile 
Betamimetic tocolytics in preterm labour Delivery within 48 hours 
Antibiotics for preterm prelabour rupture of Delivery <I week after 
membranes trial entry 
Preterm labour and delivery 
Corticosteroids after preterm pre labour rupture RDS (respiratory distress 
of membranes syndrome) 
Prophylactic oral betamimetics in pregnancy LBW (<2S00 g) 
Any prostaglandin vs placebo for induction of Operative delivery labour 
Vaginal PGEz for cervical ripening Caesarean section 
Prostaglandins VI. mechanical methods for Caesarean section 
cervical ripening 
Induction of labour Elective induction of labour at 41 + weeks 
gestation Caesarean section 
Any PG vs. oxytocin for induction of labour Operative delivery 
Endocervical PG for cervical ripening Caesarean section 
Oestrogen pretreatment before labour induction Caesarean section 
External cephalic version at term Caesarean section 
Vacuum extraction vs. forceps Significant maternal injury 
Electronic fetal monitoring plus scalp sampling Neonatal seizures 
Labour and delivery vs. intermittent auscultation in labour 
Birth chair during second stage of labour Instrumental vaginal delivery 
Prophylactic oxytocics in third stage of labour Postpartum haemorrhaae 
Umbilical vein oxytocin for retained placenta Manual removal of placenta 
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General topical area Intervention in the meta-analysis Outcome measure 
Cephalosporins vs. placebo for Caesarean Febrile morbidity 
section lendometritis 
Broad spectrum penicillin vs. placebo for Febrile morbidity 
Caesarean section lendometritis 
Metronidazole vs. placebo for Caesarean Febrile morbidity 
section lendometritis 
Prophylactic antibiotics for Broad spectrum penicillin + aminoglycoside vs. Febrile morbidity 
caesarean section placebo for Caesarean section lendometritis 
Antibiotic irrigation vs. placebo at Caesarean Febrile morbidity 
section lendometritis 
Antibiotic peritoneal irrigation vs. systemic Febrile morbidity 
antibiotics for Caesarean section lendometritis 
Broad spectrum penicillin vs. cephalosporins Febrile morbidity 
for Caesarean section lendometritis 
Oral proteolytic enzymes for perineal trauma Oedema on the third day 
Puerperium Polyglycolic acid vs. catgut for perineal repair Short-term pain 
Stilboestrol for lactation suppression Continuing lactation 1-
week postpartum 
Prophylactic phenobarbital in very low Any perilintraventricular 
birthweight neonates haemorrhage 
Natural surfactant extract treatment of RDS Broncopulmonary dysplasia (BPD) or death 
Neonatal 
Prophylactic administration of synthetic Neonatal mortality 
surfactant 
Prophylactic vitamin E in pretenn infants for 
BPD BPD 
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Chapter 5 
5. Blinding and Exclusions After Allocation in 
Randomised Controlled Trials in Obstetrics and 
Gynaecology 
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5.1 Summary 
5.1.1 Objective. The objective was to assess the methodological quality of 
approaches to blinding and to handling of exclusions as reported in controlled trials 
from obstetrics and gynaecology journals. 
5.1.2 Methods. The analysis was based on an evaluation of a random sample of 110 
reports of the parallel group trials identified in Chapter 3, in which allocation was 
stated to have been randomised, published in the 1990 and 1991 volumes of four 
journals of obstetrics and gynaecology. 
5.1.3 Results. Of the 31 trials that reported being double-blind, a mere 45% 
provided minimally sufficient descriptions of double-blinding, and only 26% provided 
additional information on the protection of the allocation schedule throughout the trial. 
Furthermore, only 16% of the reports provided any written assurances of successfully 
implementing blinding. Investigators tested the efficacy of blinding in only two trials. 
In the 49 trials in which the authors provided sufficient information for readers to 
imply that no exclusions after randomisation had taken place, only 22% explicitly 
stated that no exclusions had taken place and only one (2%) stated that an intent-to-
treat analysis had been performed. Moreover, those trials generally provided 
methodological information of inferior quality to that provided from trials that 
explicitly reported exclusions after randomisation. 
S.1.4 CODclusioDL Authors poorly reported methods used to achieve double-
blinding. The poor reporting of post-randomisation exclusions, however, causes 
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greater concern. Some of the trials reporting no apparent exclusions may not only 
have had exclusions, but may have improperly handled exclusions. Conversely, those 
reporting exclusions may have represented many of the better trials. That situation 
breeds an insidious problem, because most view trials without exclusions as less 
biased than those with exclusions. All those who rely upon the results of randomised 
controlled trials should be aware of this paradox. 
S.2 Introduction 
Given the importance of randomisation, many consider blinding and handling of 
exclusions as the next two most important methodological components of controlled 
trials (Chalmers et al. 1989). While failure to double-blind (double-mask) trials has 
been found to be associated with biased results, failure to include all randomised 
participants has not (Chapter 4). In that analysis, however, inadequate information in 
published trials hampered measurement of the associations. 
Double-blinding can be a critical element for reducing bias in trial design for at least 
a few reasons (Pocock 1983). First, participants who know they have received a new 
drug might be expected, in many instances, to respond better than untreated controls, 
even with an ineffective new drug. Second, if those treating a participant know the 
assignments, they would likely provide different ancillary care that may affect 
eventual response. Third, if evaluators know the assignments, they may alter their 
responses in the direction of their biases or overcompensate in the other direction. All 
too frequently, "evaluators will err towards recording more favourable responses on 
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the new treatment: after all, most trials are conducted in the hope that a new treatment 
will appear superior and it is only human nature to anticipate such superiority" 
(pocock 1983). 
Even though investigators might readily acknowledge the importance of double-
blinding, they frequently report their study only as 'double-blind' and do not provide 
any further clarifying information (Mosteller et al. 1980). Trials called double-blind 
are not always so. In 196 trials of nonsteroidal anti-inflammatory drugs for 
rheumatoid arthritis that were reported to be double-blind, at least 8% were probably 
not actually double-blind (G0tzsche 1989a). Furthermore, some trials become 
unblinded (Karlowski et al. 1975; Huskisson and Scott 1976). Authors infrequently 
include information on the method of blinding (Gstzsche 1989a; Mosteller et al. 
1980) and rarely test its adequacy (G0tzsche 1989a). 
Exclusions after randomisation can, for example, be because of eventual discovery of 
participant ineligibility, protocol deviations, withdrawals, or losses to followup. The 
inappropriate handling of those exclusions may greatly influence the results of a trial 
(Chalmers et al. 1981; Pocock 1982; de Jonge 1983; May et al. 1981; Sackett and 
Gent 1979). The preferred, unbiased approach is to include all randomised 
participants in the analysis, regardless of compliance with protocol. Methodologists 
refer to that approach as analysis by "intention to treat" (pocock 1983; Bulpitt 
1983). 
Trial reports, however, contain insufficient information about exclusions after 
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randomisation (Meinert et al. 1984; DerSimonian et al. 1982; Emerson et al. 1984). 
In one analysis, at least 42% of the trials provided insufficient information on 
exclusions after randomisation (Gmzsche 1989a). Many other trials may give the 
illusion of adequate information, but the impression provided may be inaccurate 
(Chapter 4). Indeed, instances have been found in which participants excluded after 
randomisation were excluded from the entire publication (Gmzsche 1989b). "Not to 
mention the existence of patients who withdrew from therapy or otherwise deviated 
from protocol is a serious failing which can lead to exaggerated claims about 
treatment efficacy" (Pocock 1983). 
The above-mentioned study examining methodological quality and bias (Chapter 4) 
analyzed trials in pregnancy and childbirth published over the last 40 years. To 
estimate the current state of reporting on blinding and exclusions in a medical 
specialty representative of pregnancy and childbirth, I conducted a systematic 
evaluation of reports of RCTs published during 1990-91 in four obstetrics and 
gynaecology journals. This probably represents the first systematic analysis of 
blinding and exclusions undertaken in this medical specialty. The systematic analysis 
of randomisation and allocation described in Chapter 3 indicated that methodological 
quality may indeed be worse than that of reports published in general medical 
journals. 
The primary general supposition was that relatively few trials would provide adequate 
speclflc Information on bllnding and exclUiloDl. However, the ropol'tl pubUlhed In 
the British Journal of Obstetrics and Gynaecology were thought to be potentially 
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of better quality than those published in other journals of obstetrics and gynaecology 
since a concerted editorial effort had been made to improve the quality of reporting in 
that journal. including publication of a series of articles providing reporting standards 
for different types of studies (Bracken 1989; Wald and Cuckle 1989) including trials 
(Grant 1989). Moreover, its reports contained higher quality descriptions of 
randomisation (Chapter 3). 
5.3 Methods 
5.3.1 Study material 
Reports were evaluated from the same four journals of obstetrics and gynaecology 
described in Chapter 3: the American Journal of Obstetrics and Gynecology 
(AJOG), the British Journal of Obstetrics and Gynaecology (BJOG). Obstetrics 
and Gynecology (OG). the Journal of Obstetrics and Gynaecology (JOG). All 
206 reports of randomised trials published in the 1990 and 1991 volumes of those 
journals were identified for that research. From those, a sample of 110 reports were 
taken for evaluation by selecting all 20 from the JOG and by taking a random sample 
(computer random number generator in EPI-INFO) of 30 from each of the other 3 
journalS. Responses on allocation concealment from the work in Chapter 3 were 
linked to the records from this study. 
A pilot study using articles from 1989 in these same journals aided in the 
development and testing of the data collection instrument for this study. For 
consistency of measurement across journals, I did all of the initial assessments. To 
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examine the reproducibility of items on the questionnaire, David A. Grimes, M.D., a 
Professor of Obstetrics and Gynaecology at the University of California, San 
Francisco, independently assessed a random sample of 10 trials. blinded to the initial 
assessments. We did not fmd any notable differences for specific information on 
blinding. but did fmd notable inconsistencies on the handling of exclusions. In 
particular. our assessments of whether a trial used 'intent-to-treat' principles 
sometimes revealed inconsistencies, largely because the reports forced this assessment 
to be made subjectively by not providing explicit information on exclusions and 
intent-to-treat Thus, variables that reflected our judgements of 'intent-to-treat' were 
not analyzed and reported on. We did, however, analyze and report on a variable 
reflecting an author's explicit statement of adhering to intent-to-treat principles. 
The data were entered interactively into an EPI-INFO questionnaire with capabilities 
for on-line checking and editing (Dean et al. 1990). Chi-squared tests were used for 
comparing nominally scaled variables. 
5.3.2 Terminology 
To reiterate concepts presented earlier, allocation concealment can always be 
implemented, seeks to eliminate or minimize selection bias, and protects the 
assignment sequence berore and until allocation (Section 2.3). On the other hand, 
blinding cannot always be implemented, seeks to eliminate or minimize ascertainment 
bias, and protects the assignment sequence arter allocation (Section 2.3). 
Comparisons of treatments may be distorted if participants, care-givers, or evaluators 
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know the treatment assignments (Pocock 1983; Altman 1991a). All may respond and 
observe differently based upon their knowledge of treatment assignments. A double-
blind trial shields all those individuals from that knowledge for the purpose of 
avoiding bias. Double-blinding becomes particularly important with subjective 
outcomes. 
In some difficult situations, double-blinding necessitates the use of a technique called 
double-dummy. Briefly, the technique involves the administration to each participant 
of one of the active treatments and the placebo (dummy) of the alternative active 
treatment (Altman 1991a). 
If either participants, care-givers, or evaluators know the assignments, then the trial is 
not double-blind. If the individuals in at least one of those categories are blinded to 
the assignments, then the trial would usually be called single-blind. Generally, 
evaluators are thought to be the most important to blind of those involved in trials. 
If possible, blinding is highly desirable. However, in some fields, blinding in general, 
double-blinding in particular, becomes difficult or impossible. Surgery exemplifies 
one such field. 
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5.4 Results 
5.4.1 Blinding 
Of the trials in this study, 65% involved pharmaceutical interventions. Overall, more 
than one-quarter of the trials reported being double-blinded, with the JOG reporting 
the lowest proportion and the other three journals reporting at about the same level 
(Table 5.1). Double-blinding was not feasible in all of the trials, however. It was 
judged to be feasible in 59% of the trials overall: 70% of the trials from AJOG, 
53% from BJOG, 50% from JOG, and 60% from OG. Thus, of trials that could 
have been double-blinded, the authors purported only 48% to be double-blind: 43% 
from AJOG, 63% from BJOG, 20% from JOG, and 56% from OG (p=O.16; 3 d.f.). 
The BJOG articles reported blinding of the assessor slightly more frequently than did 
articles from the other journals (Table 5.1). 
Of the trials that reported being double-blind, all except one provided information on 
the approach used (Table 5.2). However, overall only 45% of the reports described 
similarity of the treatment and control regimens in appearance, taste, administration, 
or other minimal prerequisites for successful double-blinding: 56% in AJOG, 60% in 
BJOG, 50% in JOG, and 20% in OG. 
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Table 5.1 
Type of blinding reported by journal 
Type of blinding AmJ BrJ 
reported by authon Obstet Obstet J Obstet Obstet 
Gynecol Gynaecol Gynaecol Gynecol Total 
Referred to as 30% 33°,4 10% 33% 28% 
double-blind; (9) (10) (2) (10) (31) 
participants, care-
given, and assesson 
blinded 
Those assessing 7% 23% 15% 10% 14% 
outcomes were (2) (7) (3) (3) (15) 
blinded 
Participants 0% 3% 0% 0% 1% 
or care-given (0) (1) (0) (0) (1) 
blinded, but not 
assesson 
No form of 630;. 40% 75°,4 57% 57% 
blinding stated (19) (12) (15) (17) (63) 
Total 100% 100% 100% 100°,4 100% 
(30) (30) (20) (30) (110) 
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Table 5.2 
Approach to double-blinding by journal 
Approach to AmJ BrJ 
double-blinding Obstet Obstet J Obstet Obstet 
Gynecol Gynaecol Gynaecol Gynecol Total 
Capsules 0% 10% 50%. 10% 10% 
(0) (1) (1) (1) (3) 
Tablets 22% 50% 0% 30% 320;0 
(2) (5) (0) (3) (10) 
Injections or 44% 0% 0% 20% 19% 
Intravenous (4) (0) (0) (2) (6) 
Double-dummy 11% 0% 0% 10% 7% 
(1) (0) (0) (1) (2) 
Other 11% 40% 50% 30% 29% 
(1) (4) (1) (3) (9) 
No information 11% 00;0 0% 0% 3% 
(1) (0) (0) (0) (1) 
Total 1000;0 100% 100% 100% 100% 
(9) (10) (2) (10) (31) 
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Only 16% provided any written assurances of successfully implementing blinding, 
with small differences among the four journals (Table 5.3). Only about one-quarter 
of the trial reports provided any additional information, beyond the minimal 
prerequisite described above, on the methods used to ensure successful blinding 
(Table 5.3). Those methods included such things as keeping the code in a secure 
location, or not breaking the code until the end of the study. The BJOG provided 
this information more frequently than did the other three combined (p=O.03, 1 d.f.). 
Table 5.3 
Assurances of successful blinding and descriptions of the protection 
of allocation sequences in double-blind trials by journal 
AmJ BrJ 
Obstet Obstet J Obstet Obstet 
Item Gynecol Gynaecol Gynaecol Gynecol 
(n-9) (0-10) (0=2) (0==10) 
Authon stated an 11% 20% 0% 20% 
assurance of (1) (2) (0) (2) 
successful 
implementation of 
blindiDg 
Authon stated aD 220/. 50% O°A. 10% 
assurance of (2) (5) (0) (1) 
protectioD of 
allocation 
sequeDcel 
Total 
(0=31) 
16% 
(5) 
26% 
(8) 
I For example. statements such as the 'code kept in a secure location' or 'code not broken until 
the end of the study.' 
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Investigators tested the efficacy of blinding in only two trials, once in each of the 
American journals. Both found substantial deciphering of the assignments. Another 
trial claiming to be double-blind reported the use of assignment by hospital number, 
which was judged unlikely to have facilitated double-blinding. Thus, at least three 
trials indicated violation of blinding. In two reports authors explicitly stated that 
investigators and participants had been kept blinded to any interim analytical results 
of their trials. Only one report stated that the investigators analysing the trial results 
had been kept unaware of the actual treatments represented by the respective groups. 
Keeping data analysts blinded, however, may not be crucial to preventing bias. 
5.4.2 Exclusions after randomisation 
Nine of the trials (8%) did not provide sufficient information on the number of 
participants randomised and analyzed to enable even an inference as to whether 
exclusions had taken place (Table S.4). All four journals had about the same 
proportion of trials reporting no apparent exclusions, but when exclusions were 
reported, trials in the BJOG were more likely to have reported less than 10% 
exclusions (p=O.002; 1 d.f.). All the trials in OG provided sufficient information on 
the number randomised and analyzed to at least infer the number of exclusions. 
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Table 5.4 
Apparent exclusions after allocation by journal 
AmJ BrJ 
Apparent exclusions Obstet Obstet J Obstet Obstet 
Gynecol Gynaecol Gynaecol Gynecol Total 
None 430/0 50% 40% 43% 45% 
(13) (15) (8) (13) (49) 
Less than or equal 17% 37% 15% 13% 21% 
to 10% (5) (11) (3) (4) (23) 
More than 10°;' 30% 10% 20% 43% 26% 
(9) (3) (4) (13) (29) 
Insumcient 10% 3% 25°;' 0% 8% 
information (3) (1) (5) (0) (9) 
Total 100% 100% 100% 100% 100% 
(30) (30) (20) (30) (110) 
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5.4.3 Tria" with no apparent exclusions after randomisation 
In 49 trials, authors reported analysing the same number of participants as 
randomised, thereby implying that no exclusions had occmred. However, only 22% 
of these explicitly stated that no exclusions had occmred after randomisation: 23% 
from AJOG, 40% from BJOG, 0% from JOG, and 15% from OG. The BJOG 
explicitly stated no exclusions more frequently than the other three combined (p=O.05; 
1 d.f.). In only one (2%) of those 49 trials (a BJOG trial) did the authors explicitly 
state that they had performed an intent-to-treat analysis, Le., they had analyzed all 
randomised participants in the originally allocated groups (Table 5.5). Furthermore, 
only 22% reported an adequate allocation concealment method, and only one adjusted 
for baseline differences in the analysis (Table 5.5). In trials that had explicitly 
reported no exclusions taking place, 45% (5111) reported an adequate allocation 
concealment method; in trials that had just implicitly reported no exclusions, only 
16% (6138) reported an adequate allocation concealment method. 
5.4.4 Tria" with exclusions after randomisation 
Fifty-two trials reported having excluded at least one participant. If authors reported 
exclusions, they usually reported the reasons for the exclusions. In these 52 trials, 
65% provided reasons by treatment group assignment. The remaining 35% provided 
reasons, but only overall and not by treatment group. Fifty percent of the trials from 
AJOG, 86% from BJOG, 29% from JOG, and 77% from OG provided information 
on the group aulgnmentl of those excluded. 
cup .... s 114 
Of these 52 trials, only four trials from BJOG and two from OG explicitly reported 
having performed an intent-to-treat analysis. Furthermore, 27% reported an adequate 
allocation concealment method, and 17% adjusted for baseline differences in the 
analysis (Table 5.5). Four trials stipulated that the exclusions were made before the 
assignment code was broken. 
Table 5.5 
Three indica ton of trial quality by reported 
information on exclusions after randomisation 
No apparent At least 1 Insufficient 
Indicator 
exclusions exclusion information Total 
(0=49) (n=S2) (n=9) (n=l1 0) 
Reported an 2% 12% 0%. 6% intent-to-treat (1) (6) (0) (7) 
analysis 
Adequate 22% 27% 11% 24% 
allocation (11) (14) (1) (26) 
concealment 
Adjusted for 
bueline 2% 17% 00/. 9% 
differences in (1) (9) (0) (10) 
analysis 
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5.5 Discussion 
5.5.1 Blinding 
Double-blinding in trials reduces bias (Chapter 4). Obstacles to its implementation 
abound, however. Indeed, investigators and participants may all attempt to decipher 
treatments, but effective methodological impediments should frustrate their efforts. 
In this study, only 31 reports cited double-blinding. That number of reports seems 
small; by the reckoning in this study, at least twice as many could have used it. 
While advising double-blinding, one must acknowledge that in certain trials, 
particularly those with objective end-points such as death, the anticipated gain in bias 
reduction may not be worth the additional difficulty and cost. However, having 
acknowledged that, double-blinding should be used if it is feasible, or the investigator 
should at least provide a rationale for not doing so. 
Distressingly, fewer than half the trials reporting double-blinding provided even 
minimal information on how it was accomplished. Even fewer reported additional 
useful information or assurances of successful blindina. Investigators rarely tested 
double-blinding. Therefore, the suspicion arises that double-blinding may have been 
ineffective in some of these trials. 
The BJOG tended to provide more detailed information on blinding than the other 
journals. Most differences were modest, however, and most were not statistically 
significant. The JOG, usually the outlier, tended to provide the least information. In 
all journals, authors rarely reported the blinding of the investigators and participants 
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to the emerging results of the trial. 
Investigators conducting a double-blind trial should -provide clarifying information: 1) 
approach (e.g. capsules, tablets, double-dummy with specifics); 2) characteristics (e.g. 
that appearance, taste, administration, or anything else minimally necessary for 
successful blinding were similar for the treatment and control regimens); 3) allocation 
schedule control (e.g. the location of the schedule during the trial and when it was 
broken for the analysis, and the special circumstances under which it could be broken 
for individual cases); 4) assurances of success or reports of failure (appraisals should 
include specifics of how the blinding failed); 5) assurances of blinding of any interim 
results that may be produced; and 6) tests of efficacy (any empirical examination of 
the degree of success attained). Tests of efficacy have their own reliability problems 
and may not always be feasible. The remainder of the above-mentioned information 
'.LI is easily reported and, along with allocation concealment information (Section ~), 
should provide minimal criteria for assessment. If nothing else, these guidelines may 
begin a dialogue on the requisite elements for implementing and reporting double-
blinding. The scientific community should reach a greater consensus on those 
elements. 
Perhaps discussion should also begin on the rather enigmatic term 'double-blinding' 
('double-masking'). Some use 'triple-blinding' or 'quadruple-blinding' depending 
upon the detail of their descriptions. Do they not mean that everyone involved in the 
trial -- partiCiPlIDtI, oraanizwl. lnveltiaatol'l ... 11OrI. care-liven. ancl tho lib --
were all blinded? A more appropriate term might clarify descriptions, such as 'full-
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blinding'. 
Moreover, it would also lead logically to specific enumeration of those blinded and 
not blinded in 'not-fully-blind' situations; terms such as 'single-blind' are just as 
enigmatically unspecific as 'double-blind.' As many as possible of the above-named 
reporting elements should also be addressed in other than fully-blind trials. However, 
the importance of providing that information has not been validated. While some 
blinding would intuitively seem better than no blinding, empirical evidence has not as 
yet confmned that presumption. 
5.5.2 Post-randomisation exclusions 
Randomisation, when successfully implemented, eliminates selection bias. Absence of 
bias persists throughout a trial, however, only if the analysis includes all randomised 
participants in the originally assigned groups. Thus, handling of post-randomisation 
exclusions becomes a crucial aspect of trial execution. Unfortunately, most trials in 
this study provided poor information. Moreover, some authors may have erroneously 
reported the numbers of participants randomised, by group. Those reported as 
randomised may have actually been the numbers of participants they had analyzed, 
after having had exclusions throughout the trial. Readers of reports thereby would 
mistakenly believe that all randomised patients had been analyzed, creating a false 
sense of security regarding the quality of the trial. 
That observation is consistent with a critique of trials from another discipline 
(G0tZSChe 1989a). In Chapter 4, an association between handling of exclusions and 
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bias was not found, and that led to the speculation that some authors did not 
accurately account for exclusions in their reports. Indeed, one investigator 
documented that practice in two trials (Gmzsche 1989b). 
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The fmdings in this chapter indirectly support that conjecture. Trials that reported 
any exclusions also more frequently reported adequate allocation concealment, an 
intent-to-treat analysis, and adjustment for baseline differences than trials that 
indicated no apparent exclusions. Because those three measures indicate good 
methodological quality, most methodologists would have expected the opposite, since 
the lack of exclusions is also usually thought to be an indicator for good quality. 
Furthermore, the reports of trials that had included explicit statements of no 
exclusions more frequently reported adequate allocation concealment than the reports 
of trials that had just implied no apparent exclusions. The deduction from these 
fmdings is that many authors reporting no apparent exclusions may in fact have 
encountered exclusions during the trial, but ignored them in the report. 
Reports from the BJOG had better information on exclusions. The authors explicitly 
stated that no exclusions had taken place over two times more frequently than did the 
authors from the other three combined. When trials reported exclusions, articles from 
the BJOG showed small losses (less than 10%) over twice as frequently as those of 
the other three combined. Reports from the BJOG also more often included explicit 
descriptions of intent-ta-treat analyses. Again, articles from JOG tended to provide 
the least informative descriptions. 
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Investigators must provide complete information on exclusions after randomisation 
including: 1) total number randomised and the numbers allocated to each group; 2) 
total number analyzed and the numbers analyzed in each group; 3) explicit 
description of the type of analysis, primarily of adherence to intent-to-treat principles 
in at least one analysis; 4) the reasons for exclusions by group, if exclusions 
occurred; 5) the outcomes at least until the time of exclusion, if exclusions occurred, 
should be included somewhere in the report, or preferably, outcomes through the end 
of the study; and 6) an explicit statement of the absence of exclusions, if relevant. 
Only with this minimal set of information can editors and readers judge the merits of 
a trial. 
5.S.3 Conclusions 
Authors poorly reported methods used to achieve full-blinding. Furthermore, in the 
two trials in which authors reported testing of full-blinding, both found that some 
assignments had been deciphered. Yet, the poor reporting of post-randomisation 
exclusions causes even greater concern. Some of the trials reporting no apparent 
exclusions may not only have had exclusions, but may have improperly handled 
exclusions. That can introduce bias. Conversely, those reporting exclusions may 
have represented many of the better trials. That situation breeds an insidious problem, 
because almost everyone views trials without exclusions as less biased. Thus, many 
biased trials may actually be viewed as 'unbiased' and many unbiased trials as 
'biased. ' Until authors comprehensively report post-randomisation exclusions, 
readers, editors, and tholO conducting systematio reviews should all be wary of this 
paradox. 
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Chapter 6 
6. Summary 
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6.1 Review of results 
6.1.1 Reporting 01 randomisation and allocation 
The generation of unbiased comparison groups in controlled trials requires proper 
randomisation, yet authors usually provide inadequate information on the process they 
used. From reports of trials from obstetrics and gynaecology journals, only 32% 
reported having used an adequate method to generate random numbers, and only 23% 
contained infonnation showing that steps had been taken to conceal assignment until 
the point of treatment allocation. Merely 9% of the reports of trials described 
adequate methods of both generation and concealment. 
Additional analyses suggest that non-random manipulation of comparison groups and 
selective reporting of baseline comparisons had occurred. In reports of trials which 
had apparently used unrestricted randomisation, the sample sizes of the treatment and 
control groups differed by less than would be expected by chance. Furthermore, in 
reports of trials in which hypothesis tests had been used to compare baseline 
characteristics, only 2% of reported tests were statistically significant, lower than the 
expected rate of 5%. 
6.1.2 Associations between methodolo&ical approaches and treatment effects 
Inadequate methodological approaches in controlled trials, particularly those reflecting 
inadequate or unclear allocation concealment, were associated with reported larger 
treatment benefits. Compared with trials in which authors reported adequately 
concealed treatment allocation, trials in which authors reported inadequately or 
unclearly concealed allocation yielded larger estimates of treatment effects (p<O.OO 1). 
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Odds ratios were distorted by 41% and 30% (adjusted), respectively. Those 
associations likely represent bias and are particularly disconcerting in light of the 
results from Chapter 3 in which over three-quarters of recently published trials 
reported either inadequately or unclearly concealed allocation. 
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Trials in which participants were excluded after randomization were not, however, 
associated with larger treatment effects, but that appeared to be due to incomplete 
reporting rather than to the unimportance of adequately handling exclusions. Lack of 
double-blinding in trials was also associated with larger treatment effects (p=O.O 1), 
albeit at a lower strength than the lack of adequate measures to conceal assignment. 
6.1.3 Reportinl of blindinl and exclusions after randomisation 
The results from Chapter 4 indicate that double-blinding protects against bias. Yet, in 
published trials from recent volumes of obstetrics and gynaecology journals (Chapter 
5), only about half the trials that could have double-blinded actually did so. 
Furthermore, when investigators attempted double-blinding, they poorly reported 
methods. Of the 31 trials that reported being double-blind, a mere 45% provided at 
least minimally sufficient descriptions for successful double-blinding, and only 26% 
provided additional information on the protection of the allocation schedule 
throughout the trial. Moreover, only 16% of the reports provided any written 
assurances of successfully implementing blinding and only two tested the efficacy. 
The poor ",portinS of poat.randomtzatton oxcluaJoftl in recent volume. of obstetric. 
and gynaecology journals, however, causes greater concern. In 49 trials with no 
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apparent exclusions after randomization, only 22% explicitly stated that no exclusions 
bad taken place after randomization and only 2% stated that an intent-to-treat analysis 
bad been perfonned. Moreover, those 49 trials generally provided methodological 
information of inferior quality to that provided from trials that reported exclusions 
after randomization. 
These results from Chapter S generally support the fmdings from Chapter 4. Some of 
the trials reporting no apparent exclusions may not only have had exclusions, but may 
have improperly handled exclusions. Conversely, those reporting exclusions may have 
represented many of the better trials. That incongruity fosters a furtive problem, 
because almost everyone views trials without exclusions as less biased than those with 
exclusions. All who use the results of randomized controlled trials should be aware 
of those potential inconsistencies in the reporting of exclusions. 
6.2 Implications for meta-analyses 
6.2.1 Exclusion or trials rrom meta-analyses 
The results in this thesis suggest some implications for meta-analyses. Trials using 
inadequately concealed allocation schemes should be the fIrst to be considered for 
elimination from meta-analyses for quality concerns. Dealing with trials, however, 
that have used unclearly concealed approaches can be more problematic. They 
preferably should be excluded, as some do (peto 1987). If that practice were carried 
out at the present time, however, meta-analysts in many medical specialties would be 
left with very few, if any, trials for their reviews. Indeed, the examinations in this 
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thesis of the meta-analyses from pregnancy and childbirth topics revealed that many 
did not contain even one trial that had used an appropriate allocation concealment 
scheme. Advocating the exclusion of all inadequately and unclearly concealed trials 
under such situations might be inappropriate, for that would leave the analyst without 
any trials to analyze. 
6.2.2 Adjustments to the results of presumed biased trials 
Some may argue for including inadequately and unclearly concealed trials, but using 
adjustments for the bias. While that approach may have appeal, it is quite risky 
because of the great uncertainty in assigning adjustment factors. In estimating the 
effects of unclearly concealed trials on treatment effects in this thesis, statistically 
significant heterogeneity existed among the meta-analyses. Thus, using an overall 
factor based on this study may not even apply to another meta-analysis of perinatal 
trials let alone another meta-analysis in a totally different medical specialty. 
6.2.3 Use of • nndom effeds model 
Using a random effects model for analysis in some situations may be helpful because 
it would account for an additional component of between-trial variance. That might 
be particularly useful when trials using combinations of adequately, unclearly, and 
inadequately concealed approaches are included in a meta-analysis because of the 
likely additional heterogeneity and greater between-trial variance. The confidence 
interval for the overall odds ratio using a random effects model might be more likely 
to encompus the true effoct than the overall odds ratio using a fixed effect model. 
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Nevertheless, if an analyst includes biased trials in the meta-analysis, the point 
estimate of the summary odds ratio would still be biased. That would have to be 
clearly explicated in the discussion of the results. Of concern also is that the 
between-trial variance could be relatively small, particularly if all the trials used 
unclearly concealed allocation. (Remember that the heterogeneity in the unclearly 
concealed trials was not too different from that in the adequately concealed trials.) 
With small between-trial variance among unclearly concealed trials, the confidence 
interval from a random effects model would be very similar to that from a fIXed 
effect model and not of much assistance. Thus, while the use of a random effects 
model may be helpful in some situations, it is no panacea, and does not alter the need 
for carefully phrased qualifications to accompany quantitative results based on 
potentially biased trials. It certainly does not supplant the need for trials that have 
used adequate allocation concealment. 
Moreover, the random effects approach cannot be viewed as a panacea for other 
reasons. Rather unrealistic asswnptions pertain to the heterogeneity between trials 
being represented by a single variance and the between-trial distribution being Normal 
(Thompson 1993; Thompson and Pocock 1991). Because of those and other 
problems, Thompson (1993) suggests using the random effects method as a type of 
sensitivity analysis, investigating "how much the overall conclusions change as the 
assumptions underlying the statistical methodology also change." The use of random 
effects models in general warrant further exploration, but particularly with respect to 
between-trial variance caused by variations in methodoloaica1 quality. 
6.2.4 Tentative suggestions 
Restricting meta-analyses to adequately concealed trials seems prudent. If an 
insufficient number are available, potentially biased trials may have to be included 
and sensitivity analyses performed. The results, however, would need to be 
appropriately qualified. 
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Another potentially viable option would be to stratify by, and separately analyze, the 
adequately and unclearly concealed trials. A test of heterogeneity between those two 
strata could be implemented. In general, however, the issue of proper handling of 
poor quality (biased) trials in meta-analyses deserves greater attention. Section 6.3.3 
contains a recommendation for the next step in providing that attention. 
6.3 Further research 
6.3.1 ReplicatioD 
Other investigators certainly should implement analyses on other data sets similar to 
those contained in this thesis. As the Cochrane Collaboration grows, a great many 
opportunities will materialize to replicate this work. Indeed, even the Cochrane 
Collaboration Pregnancy and Childbirth Module has increased in size since this 
analysis began, and someone could already extend this research to additional meta-
analyses within that module. 
Beyond replication, suggestions tor further research are oft'ered in the next two 
sections. The following topics represent the two highest priorities. 
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6.3.2 Unpublished trials and estimates of treatment effects 
In Chapter 4, only published trials were used for analysing the association between 
methodological quality and treatment effects, for obvious reasons. Thus, the results 
only pertain to published information. But consumers of RCTs, particularly meta-
analysts, need to be able to deal with unpublished trials. That becomes particularly 
important with the potential for publication bias. 
Additional research should delve into this realm. The association between 
unpublished trials and treatment effects should be examined, with the study design 
resembling that found in Chapter 4. The unpublished trials as a group would 
represent a quality level that would be compared against the adequately, unclearly, 
and inadequately concealed trials in the database. 
6.3.3 Allocation concealment and heterogeneity in meta-analyses 
From Chapter 4, differential treatment effects appeared to be related to allocation 
concealment From Chapters 3 and 4, many trials did not report adequate 
concealment The suspicion that differing levels of allocation concealment within 
meta-analyses cause greater heterogeneity appears warranted. Thus, accounting for 
allocation concealment in a meta-analysis, e.g. by exclusion of inadequately concealed 
trials or by separate analyses according to allocation concealment strata, may address 
much of the apparent heterogeneity. 
That illUCl mould be oxplond in a tample of meta·anal)'.... I anticipate doina 10 
with the data set used in Chapter 4, but hope that other investigators will analyze 
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other data sets with the same intent 
6.4 Comments on randomisation 
6.4.1 Shared responsibility for poor reporting 
Beyond the discussions in the chapters, a few particulars of randomisation warrant 
more comment That such a vast majority of the reports of trials failed to describe 
adequate methods of randomisation generation and randomisation concealment is 
disappointing, particularly since inadequate descriptions appeared to be associated 
with biased results. Those deficiencies in randomisation partly reflect the fact that 
people with an interest in methodology, such as myself, have failed to provide 
adequate guidance in the literature. 
6.4.2 Generation of the allocation sequence 
Nevertheless, having already referred to deficiencies in the literature, available texts 
generally attend well to the details of generating randomised assignment schedules. 
One aspect of the process, however, deserves greater attention. If randomisation 
involves blocking, the block size should be randomly varied to reduce the chances 
that the assignment schedule will be inferred by those responsible for recruiting 
participants. 
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If the trial is not blinded and the block size is fIXed, particularly if the size is small (8 
or less), the allocation schedule would be too predictable. The block size would 
invariably be deciphered and selection bias would be introduced, regardless of the 
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effectiveness of allocation concealment. Moreover, even if the study is double-
blinded, many treatments have obvious side-effects which may eventually lead to the 
deciphering of the block size. Thus, even in those instances, varying the block size 
would be recommended as a precautionary measure so as not to jeopardize the 
effectiveness of the randomisation process. 
6.4.3 Need for greater empbuis on allocation concealment 
Many of the available texts, on the other hand, contain less useful information on 
highlighting the importance and mechanics of randomisation concealment. That 
deficiency needs to be addressed in more detail. 
For those involved in implementing a trial that has not incorporated proper procedures 
for randomisation concealment, the challenge of deciphering a randomisation scheme 
frequently presents too great a temptation to resist. Succumbing to that temptation 
may at times be innocent and a reflection of human inquisitiveness and ingenuity 
rather than scientific malevolence; but, whatever the motivation, the net effects are the 
same if the introduction of selection bias invalidates the comparisons made in the 
trial. 
At least a few investigators have been sufficiently astute to identify and candid 
enough to report the deciphering of their schemes (King 1959; Kirkland et al 1960; 
Wood et al 1981; Lazar et al 1984). Moreover, I have heard many 'off the record' 
admillioDl of dociphorina· Mothodoloaicai Hfeauardt mllit be eltabliahed to impede 
investigators from contaminating trials with bias. 
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6.4.4 The leniency o( judgements on concealment 
While many readers of this thesis may believe the judgements on the quality of 
allocation concealment were too harsh, the judgements may actually have been too 
lenient For example, sealed envelopes are more susceptible to manipulation through 
human ingenuity than other approaches. Therefore, some consider them as generally 
less desirable (pocock 1982). If investigators use envelopes, every methodological 
nuance should be addressed to subvert attempts at breaking the randomisation, and, of 
course, all methods should be reported. Only about a quarter of the reports in the 
obstetrics and gynaecology journals in which the use of envelopes for concealment 
was described met the minimum criteria of using sequentially numbered, sealed, 
opaque envelopes. All of those components are important (Altman and Oore 1990), 
but, in addition, the trials should have reported that the envelopes had been opened 
sequentially, and only after the participant's name and other details had been written 
on the appropriate envelope (Bulpitt 1983). Furthermore, using pressure sensitive or 
carbon paper inside the envelope transfers such information to the assigned allocation 
and thus creates a valuable audit trail. 
Reports in which authors stated the allocation schedule to have been prepared by the 
pharmacy were classified as having used an acceptable approach to concealment 
(Altman and Dore 1990). The compliance of pharmacists with proper randomisation 
concealment methodology in these trials is unknown, however, and the precautions 
taken should have been reported, but generally were not In the past, in certain 
instances, pharmacists have been responsible for gron distortions of assignment 
schedules. For example, one large pharmacy allocated all participants to one ann of a 
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two-group trial because they ran out of one drug on the weekend. Another large 
pharmacy generated the allocation schedule thinking that 'alternate assignment' met 
the randomisation criteria. Investigators should not assume that pharmacists, and 
others involved in their trials for that matter, are knowledgeable in RCT methodology 
and should ensure that their research partners follow proper trial procedures. 
The use of nwnbered or coded containers helps to prevent foreknowledge of treatment 
assignment, but the criteria in this thesis only required a statement that such 
precautions had been taken, without requiring further details of how this had been 
achieved. Assurances that all of the containers were of equal weight and similar 
appearance, and that some audit trail had been established (such as writing the names 
of participants on the empty bottles or containers), would help readers to assess 
whether randomisation was likely to have been concealed successfully. Similarly, 
although central telephone randomisation was counted as an acceptable approach to 
allocation concealment, that general criterion might be regarded as having been lenient 
in not requiring details of the actual procedures used. 
With all approaches, the person(s) who prepared the randomisation scheme ideally 
should not be involved in determining eligibility, admjnistering treatment, or assessing 
outcome. When considered for a moment, the rationale for that proscription becomes 
obvious. Regardless of the methodological quality of the allocation generation and 
concealment process, such an individual would always have access to the allocation 
schedule and thus the opportunity to introduce biu. Nevertheless, under some 
extraordinary circwnstances, someone may have to prepare the scheme and be 
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involved in the trial. In these instances, the investigators must make sure that the 
assignment schedule is unpredictable and locked away from even the person(s) who 
generated it. Thus, who prepared the scheme should have been reported, and the 
criteria used in this thesis could again be assailed as being too lenient in not requiring 
the presentation of those details. 
6.4.5 Improving the standard of reporting 
While improving the standard of reporting is surely a shared responsibility, omission 
of randomisation details to date has probably been primarily an author-based 
phenomenon rather than due to journal editors extracting important material from 
manuscripts. Moreover, refereeing and editorial work cannot improve what was 
actually done in a trial; only how well it was reported. Thus, arguably the burden for 
improvement should fall primarily upon investigators and authors. 
Protestations from authors about lack of space does not constitute an acceptable 
excuse for omission. Space will always be a limitation (albeit, much less so in 
electronically published reports); the issue is the relative importance of the topics 
addressed. Information with little bearing on scientific validity has been included in 
many reports while critical elements of the randomisation process has been omitted. 
Yet in a well-executed, blinded, randomised controlled trial, many aspects other than 
randomisation become almost scientifically inconsequential to the treatment 
comparisons since they would have been applied equally to unbiased comparison 
groups. 
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Certainly, I would not wish to promote a cavalier attitude toward the other 
methodological elements of trials: they must be adequately addressed, and surely some 
have to be adequately described for readers to interpret the rmdings and extrapolate 
the results. In particular, authors must present more complete information on 
exclusions after randomisation and include additional information on blinding 
procedures. Yet, proper reporting of the randomisation procedures should be of the 
highest priority, and one should have little confidence in those trials failing to provide 
that information. 
6.5 Final thoughts 
This thesis research has clearly revealed the vital importance of adherence to proper 
design principles in conducting trials. Investigators must properly design, 
meticulously execute, and completely report their trials. In particular, if they do not 
conceal treatment allocation, bias will likely distort their results. Investigators, 
editors, and readers need to be aware of that association. Randomised controlled 
trials supposedly minimize bias; the research community and public should expect 
nothing less. 
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